subject index for volume 44 - core.ac.uk · anemia arf, endogenous epo deficit (abst) 1411 ... (...

Subject Index For Volume 44

AAcetylcholine metabolism, brain synaptosomes, CRF.... 630Acidification, renal capacity, lithiasis (abst) 1418Acidity, titratable, urinary stone risk factors 120Acidosis, metabolic, growth factor expression 1224Acquired cystic kidney disease

hemodialysis (abst) 1412transplantation, CsA and 613

Acute pancreatitis, post-transplant (abst) 1425Acute phase reactans C3a, /3-m, HD (abst) 1437Acute renal failure

African honey bee (abst) 1455Bolivia (abst) 1436bone marrow transplantation (abst) 1477cholera, renal injury (abst) 1420clinical analysis (abst) 1452CsA, liver transplantation (abst) 254diagnosis/management, computer systems (abst) 907EPO deficit, anemia (abst) 1411gene expression as recovery markers (abst) 1178immunoallergic, children, NSAIDs (abst) 467liver transplantation (abst) 1499Malarie Falciparum (abst) 1455mortality rates (abst) 1430neuroleptic malignity syndrome (abst) 907obstetrics (abst) 1441

oliguric, furosemide (abst) 1451post-cardiovascular surgery, CAVH (abst) 1416pregnancy (abst) 1431renal artery embolism (abst) 1462, 1480sepsis and (abst) 1430septic abortion (abst) 1424treatment, Cuba (abst) 1493

Acute vascular rejection, OKT3 (abst) 1416Addison's disease

glucocorticoids, panhypopituitarism 1130glucocorticoids, panhypopituitarism (abst) 1196

AdenosineK channels, ANF, Ang II glomerular responses

(abst) 240medullary TAL as source (abst) 239

Adhesion moleculeshuman kidney 147PMMA dialysis membrane (abst) 1394renal inflammation 42:S-27

Adolescents, hypertension, BP monitoring (abst) 1477Adrenal masses, hypertension (abst) 1473Adrenal microadenomas, hypertension, aldosterone

(abst) 916Adrenalectomy, protein, enzyme activity (abst) 263Adult polycystic kidney disease, epidemiology (abst) . . . 1424African honey bee, ARF (abst) 1455Albumin

excretion, oral protein load (abst) 907as HD mortality predictor 115

Aldosteroneadrenal microadenomas, hypertension, renin (abst). . . . 916modulates PNA-labeled cells, CD epithelium 537

Alkalosis, proximal tubule/TAL adaptation (abst) 1463Allergic reactions

HD (abst) 1414incidence, HD (abst) 1422

Allograftschildren, glomerulopathy 43:S-95children, growth hormone treatment 199children, recurrent disease in 43:S-91CMV-seropositive, immunoprophylaxis (abst) 266creatinine clearance as GFR marker, CsA (abst) 255donor related non-Hodgkin lymphoma (abst) 466flow cytometric cross match, antibody status (abst)... 1393ULA matching, effect on graft survival (abst) 1190impairment, cyclosporine triple therapy (abst) 1425malignancy in recipients (abst) 1191

pneumocystis carini pneumonia, prevalence (abst) .... 264rejection, Banif classification 411rejection, children, T cell signaling role 43:S-3rejection, detection by dopplersonography (abst) 256rejection, embolization with ethanol (abst) 1468rejection, glycolipid blood group antigens 1289rejection, HLA-identical recipients (abst) 468rejection, intrarenal CsA deposits (abst) 1402rejection, OKT3 therapy (abst) 468, 1416rejection, serum hippuric acid (abst) 261

rejection, tissue specific recognition (abst) 1193rejection, VCAM-l expression 805rupture, cyclosporine (abst) 1471

specific glomerular lesion 42:S-104steroids, azathioprine, CsA (abst) 1443survival, cyclosporine, cadaver grafts (abst) 1418

a-interferon therapy, HBV-associated GN (abst) 1184Alport syndrome

COL4AS gene analysis (abst) 250COL4A5 mRNA variant splicing 1316COL4A5 probe, phenotype correlation (abst) 1183COL4AS single base insertion 1091

multicenter study, Italy (abst) 1399Aluminum

adynamic IDDM, non-diabetic uremia (abst) 1445bone cells, cytokines (abst) 1498bone metabolism, normal renal function (abst) 1498bone stores, measurement (abst) 1498deferoxamine test dosage (abst) 1458removal, desferroxamine therapy (abst) 1497

Aluminum absorptioncitrate, RF (abst) 253erythrocytic dysmorphism, HD, uremia (abst) 1400erythropoiesis, rats (abst) 1463erythropoiesis, renal failure (abst) 1463hemoperfusion, HD, desferioxamine (abst) 910

Aluminum hydroxidehyperphosphatemia, calcium acetate therapy (abst).... 260plasma, bone aluminum concentration, uremia (abst) . 1464

Aluminum toxicityiron absorption, EPO therapy, anemia, HD (abst)... . 1467

osteodystrophy, "suppressed" PTH 860role in immunosuppression (abst) 1453

1546

Subject Index: Vol. 44 1547

treatment (abst) 1498Ambulatory blood pressure monitoring (ABPM)

arterial hypertension, adolescents (abst) 1477arterial hypertension (abst) 1481hypertension, HD (abst) 1444

white coat" hypertension (abst) 1444Amino acids

cognitive function, HD (abst) 908intra-arterial infusion, GFR, glucagon (abst) 1413profiles, CAPD (abst) 1188supplementation, muscle metabolism (abst) 465

Amyloid arthropathy, C-reactive protein levels (abst)... 1395Amyloid deposits, proteinase inhibitors (abst) 1409Amyloidosis

f32-m synthesis, HD, lymphokines (abst) 1409dialysis-related (abst) 1461nephrotic syndrome (abst) 1183primary, survival factors (abst) 1408renal (abst) 1431uremia, IL-2R serumlsynoviai fluid levels (abst) 1395

AN69 membranes, anaphylactoid reactions (abst) 1481Analbuminemia, ovariectomy, triglycerides (abst) 1193Analgesic nephropathy 42:S-86Anaphytactoid reactions, AN69 membranes (abst) 1481Anemia

ARF, endogenous EPO deficit (abst) 1411EPO therapy, aluminum intoxication (abst) 1467EPO therapy, CAPD, HD (abst) 1479EPO therapy, CRF, children (abst) 911EPO therapy, uremia, not on dialysis (abst) 1434EPO therapy (abst) 912EPO with intravenous iron, HD (abst) 911post-transplant (abst) 1423rHuEPO therapy, cardiovascular aspects 1309rHuEPO therapy, chronic rejection (abst) 470rHuEPO therapy, estimating Hb/Hct (abst) 1441rHuEPO therapy, pre-dialysis (abst) 1475therapy, brain cell function (abst) 911zinc levels, CRF, HD (abst) 1484

Anergy, CD4 T cell, tubular epithelial cells 1030Angiotensin-( 1-7), phospholipase, Na transport 932Angiotensin converting enzyme (ACE)

hemodialysis (abst) 1437hypertension, diuretics (abst) 1420hypertension, immunosuppression (abst) 1439renovascular hypertension, Ang II receptors (abst).... 245renovascular hypertension (abst) 245

Angiotensin converting enzyme (ACE) inhibitionantihypertensive agents, Ca antagonist, OS (abst).... 1178antiproteinuric effect, renal hemodynamics (abst) .... 1195bradykinin, efferent arteriolar dilation 545brain ANF, rats (abst) 246brain ANF, renal insufficiency 24HBV, glomerulonephritis (abst) 1184hemodynamics, proteinuria 579renal hippuran extraction, rats (abst) 1194renovascular hypertension, Nephrology Forum 1379

Angiotensin IIANF, adenosine glomerular responses (abst) 240AVP, MC expression (abst) 242catecholamines, low-protein diet 285elevation, polydipsia, HD 107mesangial response, glucose, ANP 518

Angiotensin 11 receptorslocalization, rat kidney 42:S-40

regulation, ADPKD (abst) 243renovascular hypertension (abst) 245streptozotocin-induced DM, rats (abst) 1392

Angiotensin inhibitors, nephrotic syndrome (abst) 1415Angiotensin type-i receptor mRNA, expression, rats.... 331Anion exchange, protein identified in proximal tubule .. . 565Anti-CD3 monoclonal antibodies (abst) 1198Anti-DNA monoclonal antibodies (abst) 905Anti-glomerular basement membrane nephntis

crescentic, urine urokinase activity (abst) 1181

glomerular expression TGF-13, PDGF (abst) 905glomerular fibnnolytic activity 557HLA-DR and -DQ types 307

Anti-N-like antibodies, clinical significance (abst) 1407Anti-neutrophil cytopiasmic antibodies (ANCA)

diagnostic significance of detection (abst) 906renal perfusion of proteinase 3 (abst) 1194

Anti-thymocyte antiserum, ON, MCP-l expression 1036Antibiotic therapy, endocarditis, ON (abst) 469Antibody status, flow cytometric cross match (abst).. . . 1393Anticoagulant factor protein S, membranous ON (abst) . 1398

Anticoagulants, prophylactic use, nephrosis (abst) 265Antidiuretic hormone, antagonist OPC-3l260, SIADH .... 19Antigens

expression, rejected ABO incompatible grafts 1289presentation by parenchymal cells 927

Antihypertensive agentsACEi, Ca antagonist, glomerulosclerosis (abst) 1178isolated systolic hypertension, renal function (abst).. .. 911long-acting (abst) 908LVH regression, uremia, HD 881

Antilymphocytic globulinsdelayed graft function (abst) 913lymphocytic molecules, rosette phenomenon (abst).... 465monoclonal gammopathy, post-transplant (abst) 265

Antimicrobial prophylaxis, recurrent UTI (abst) 1434Antineutrophil cytoplasmic autoantibodies (ANCA)

glomerulonephritis (abst) 1184lupus nephritis 1185oculo-renal syndrome (abst) 1431steroids, renal vasculitides 215transplantation, polyarteritis (abst) 469vasculitis prevalence, dialysis (abst) 252

Antisense oligonucleotides, IL2R gene expression (abst)... 255Aplastic osteodystrophy, aluminum, "suppressed" PTH... 860Apolipoproteins

epitopes of LDL, HD 1360lipoprotein(a), diabetics, HD (abst) 908phenotypes, HD, with/without DM 1062ratio in uremia, fibric acid, clinofibrate 1352

Area under the curve, prevents CsA toxicity 436Arginine synthesis, chronic renal failure 676Arginine vasopressin (AVP)

Ang II, MC expression immediate early genes (abst)... 242collecting tubule action, changes in pH 1235extracellular Na, [Ca2'11 increase 755

Arterial pressurechanges and metal ions (abst) 908EPO therapy (abst) 1482, 1490

Arteriovenous fistulaautoexpanded metallic endovascular prosthesis (abst). 1491biopolymeric prosthesis, HD (abst) 1491coagulation inhibitor deficiency (abst) 469color Doppler ultrasonography (abst) 1470femoral, HD (abst) 470

1548 Subject Index: Vol. 44

opening/closing, hemodynamics, HD (abst) 1465Aspiration-sclerotherapy, renal cysts (abst) 1177Atenolol, renal function, diabetic nephropathy (abst) ... 1197ATG-Fresenius prophylaxis with OKT3 (abst) 266ATP, cellular mechanisms, calcium activity (abst) 241ATP analogues, UTP, phospholipase (abst) 258ATP-ase dependent Na/K pump, liquorice abuse (abst) . 1400Atrial natriuretic factor (ANF)

ACE inhibitors, rats 24ACE inhibitors, rats (abst) 246Ang II, adenosine glomerular responses (abst) 240biologic/physical characteristics 937CAPD (abst) 1465

Atrial natriuretic peptide (ANP)BP response, high salt intake (abst) 246insulin, CRF (abst) 910mesangial response, glucose, Ang II 518Na, water transport, rat CCD 30natriuretic action (abst) 472streptozotocin-induced DM (abst) 471

Autoexpanded metallic endovascular prosthesis, HD(abst) 1491

Autoimmune glomerulonephritis 294Autologous blood transfusion

alloimmunized patient, SLE, anemia (abst) 469Autosomal dominant polycystic kidney disease (ADPKD)

Ang II receptors (abst) 243clinical management 42:S-74clinical study, Toronto 1101clinical survey, gene carriers (abst) 1425clinical utility of genetic markers (abst) 1405glycoprotein expression, ECM (abst) 243immunohistochemical detection of renin (abst) 243morphology/immunocytochemistry, rats (abst) 243polymorphism of PGP for diagnosis (abst) 244

Azathioprineafter triple therapy (abst) 255cyclosporine, outcome (abst) 1481

cyclosporine triple therapy, graft function (abst) 1425hypersensitivity (abst) 261leukopenia, GM-CSF, post-transplant (abst) 1191steroids, CsA double therapy (abst) 1443steroids, hepatitis B reactivation (abst) 1427

Aztreonam-cloxacillin, UTI prophylaxis (abst) 1440

BB7/CD28 pathway in dialysis patients 359Bacteremia

chronic HD, multicenter study (abst) 467enterococcus, endocar(Jitis (abst) 1418in renal failure (abst) 1470

Bacterial endocarditis, antibiotic therapy (abst) 469Banff classification, transplant pathology 411Bartter/Gitelman syndrome (abst) 1197Bartter's syndrome 401Benzbromarone, uricosuric efficacy of (abst) 267Benziodarone, hyperuncemia, transplantation (abst).... 1480Berger's disease, clinical histology (abst) 1403fl-glycosylated erythropoietin

cell mediated immunity, HD (abst) 912platelet aggregation, HD (abst) 912

I3 integrins, membranous nephropathy (abst) 1392f2 microglobulin

acute phase reactans C3a, HD (abst) 1437amyloid deposits, plasma proteinase inhibitors (abst) . 1409

granulocyte inhibitory protein isolated, HD (abst) 253HD, amyloidosis, lymphokines (abst) 1409IL-I, TNF release (abst) 1472

11 -/3OHSD, prednisolone/prednisone ratio (abst) 263Bicarbonate dialysate

COPD ventilatory function on HD (abst) 1462PD, buffer, biocompatibility (abst) 1394

Biopolymeric prosthesis, HD (abst) 1491

Biopsybone marrow, familial Mediterranean fever 834renal, follow-up (abst) 1181renal, FSGS, minimal change disease (abst) 905renal, interstitial nephritis (abst) 1179renal, lupus nephropathy (abst) 1406renal, systemic vasculitis (abst) 1429renal percutaneous (abst) 1416, 1420, 1458

Blood pressurearterial, isradipine, renal hemodynamics (abst) 1429chronic HD patients, EPO therapy (abst) 1413lisinopril, microalbuminuria, proteinuria (abst) 1407nocturnal changes, cerebral ischemia (abst) 246post-high sodium intake, ANP (abst) 246

Blood transfusions, autologous, EPO therapy (abst) 469Blood volume monitoring, non-invasive, dry weight, HD... 851Body composition

altered, post-transplant, CsA (abst) 261altered, post-transplant, glucocorticoids (abst) 261CRF, HD (abst) 1449ESRD, dialysis modality (abst) 261

Body mass index (BMI)cardiovascular morbidity, hypertension (abst) 1453obesity, essential hypertension, CV risk (abst) 1419

Body position, hypertension, hemodynamics (abst) 1446Bone densitometry

CAPD (abst) 1478hyperparathyroidism (abst) 1485

Bone densitychildren, hypercalciuna (abst) 1176children, hypercalciuric/normal (abst) 1421chronic HD, hyperparathyroidism (abst) 253idiopathic calcium stone formers (abst) 264post-transplant (abst) 267transplantation, HD (abst) 1457transplantation, post-PD (abst) 1449

Bone histology, PTH, vitamin D3, radiology, ESRD.... 1071Bone histomorphometric pattern, IDDM (abst) 1445Bone marrow

biopsy, familial Mediterranean fever 834changes, post-EPO therapy, HD (abst) 1185transplantation, risk factors, ARF (abst) 1477

Bone metabolismaluminum (abst) 1498serum procollagen type-I, HD (abst) 909

Bradykininduring ACE inhibition 545Na, water transport, rat CCD 30

Brain cell function, renal anemia, CAPD (abst) 911

Brain death, diagnosis, transcranial Doppler (abst) 1459Brain natriuretic peptide (BNP) 937Brain synaptosomes, acetylcholine metabolism 630

CCadaver renal grafts

long-term renal function (abst) 1439retransplantation (abst) 1473


survival rates, cyclosponne (abst) 1418survival rates, Hispanoamerica (abst) 1405Third World, Hispanoamerica, Cuba (abst) 1420utilization in children 43:S-99

Cadmium exposurerenal dysfunction (abst) 250renal tubular acidosis (abst) 1176

Calbindin-D28k, gene expression, murine kidney 322Calcitonin, PTH, calcium stone formers (abst) 139722-oxa-calcitriol

PTH secretion, Ca transport, CRF (abst) 467secondary hyperparathyroidism, calcium metabolism .. 551

Calcitriolextrarenal synthesis, uremia 134PTH, 22-OXA-1,25D, Ca transport, CRF (abst) 467

Calcitriol therapychronic HD (abst) 1455hyperparathyroidism, chronic HD (abst) 1408immunological effects, HD, uremia (abst) 1398intravenous, post-dialysis bolus (abst) 14681,25(OH)2D3, PTH, CAPD (abst) 1399osteocalcin levels, chronic HD (abst) 1408renal osteodystrophy, CRF (abst) 909risks/benefits, chronic HD (abst) 259severe HPT (abst) 253

Ca + ions, arterial pressure changes (abst) 908[Ca2], increase, AVP-induced, extracellular Na 755Calcium2 uptake, glucose elevation, VSMC 344Calcium

22-oxa-calcitriol, hyperparathyroidism 551cell volume, pH, RAS oncogene expression (abst) .... 241iron, oxidant-induced DNA damage 1228kinesis, renal osteodystrophy (abst) 909quantification, VS MC, hypertension (abst) 244signaling, MC, protein kinase C (abst) 1397transport, PTH, calcitriol, 22-OXA-1,25D, CRF

(abst) 467urinary creatinine, children (abst) 1176

Calcium acetate, aluminum hydroxide therapy (abst) .. . . 260Calcium antagonists

ACEi, antihypertensive agents, OS (abst) 1178ACEi, hypertension, immunosuppression (abst) 1439cyclosporin A therapy, post-transplant (abst) 1496renal graft function (abst) 913

Calcium channelsintracellular Ca in VSMC, rats (abst) 1393mesangial cells (abst) 241

Calcium oxalate crystalsepitaxial growth, CaCO3 crystals (abst) 472modified, Tamm-Horsfall protein, citrate (abst) 263

Calcium-phosphate metabolismhistomorphometric bone pattern (abst) 1445

Calcium renal stoneshypercalciuria, PTH, calcitonin (abst) 1397hypocitraturia, without calculi (abst) 1442urinary citrate relative to calcium (abst) 1442

Calcium salts, calcium dialysate (abst) 265Caloric malnutrition, protein catabolic rate (abst) 1467cAMP- and dopamine-dependent phosphoprotein

(DARPP-32) 495Candida peritonitis, PD (abst) 1452Captopril

diagnosis, renovascular hypertension (abst) 1448inhibits metalloproteinases 1266renal function, diabetic nephropathy (abst) 1197

scintigraphy, renal artery stenosis (abst) 1495Carbohydrate metabolism

body composition, CsA, lipids (abst) 261nifedipine, CRF (abst) 1455vitamin B6, CRF (abst) 1456

Carcinomarenal cell, cytokine expression 585renal cell, Von Hippel-Lindau syndrome (abst) 250

Cardiac function, systolic/diastolic, dialysis (abst) 1499Cardiac gated blood pool scan, ESRD (abst) 1186Cardiovascular aspects of rHuEPO therapy 1309Cardiovascular complications

EPO therapy, HD (abst) 1470post-transplant (abst) 1464

Cardiovascular diseasemorbidity, hypertension, BMI (abst) 1453risks in cyclosporine therapy (abst) 1424risks in essential hypertension, obesity (abst) 1419

Cardiovascular surgery, ARF, CAVH (abst) 1416Carnitine losses, HD (abst) 1494Cascade lipidapheresis, hypercholesterolemia (abst) 916Catecholamines, Ang II, low-protein diet 285Cathechol-O-methyltransferase mRNA, developing

kidney 726Catheters, pentoneal

exit-site infection (abst) 915malfunction, nonoperative repair (abst) 1189migration (abst) 1477post-operative complications (abst) 919Swan neck (abst) 1472

CD4 T cell anergy, tubular epithelial cells 1030Ceftriaxone-cloxacillin, UT! prophylaxis (abst) 1440Cell adhesion molecules

expression, human kidney 147leukocyte-endothelial, renal inflammation 42:S-27renal inflammation 42:S-27vascular, allograft rejection 805

Cell depolarization, inhibition of K channels (abst) 237Cell mediated immunity, EPO, HD (abst) 912Cell mediated lympholysis, post-transplant (abst) 1427Cell proliferation, RAS oncogene expression (abst) 241Cellulose triacetate dialyzer (abst) 1494Central nervous system, magnetoencephalography

(abst) 914Cerebral hemorrhage, risk factors, dialysis 1086Cerebral ischemia, nocturnal BP changes (abst) 246Cerebrovascular complications, post-transplant (abst)... 1464cGMP inhibits Cl flux n the mTAL 741Chagas disease, transmission (abst) 1461, 1462Children

acute rejection, steroids, OKT3 therapy (abst) 1454allograft glomerulopathy 43: S-95bone density, hypercalciuria (abst) 1176CRF, anemia, EPO therapy (abst) 911CRF. growth hormone therapy (abst) 1185CRF, hyperparathyroidism (abst) 1417CRF, protein diet (abst) 1417focal segmental glomerulosclerosis (abst) 1426OFR determination methods (abst) 1409growth hormone therapy, allografts 199hypercalciuria, bone mineral content (abst) 1421hypertension (abst) 1407immunoallergic ARF, NSAIDs (abst) 467maintenance dialysis 43:S-l04nephrotic syndrome, CsA toxicity (abst) 1182


nephrotic syndrome, cyclosporin (abst) 906nephrotic syndrome, FSGS (abst) 1182nephrotic syndrome, interleukin (abst) 1182OPD nephrology clinic (abst) 1435peritoneal kinetics, CAPD (abst) 1457post-transplant hospitalization 43:S-83rHuEPO therapy, anemia, CRF (abst) 1411

rHuEPO therapy, pre-dialysis (abst) 1402transplantation, ages one to five years 43:S-40transplantation, cadaver grafts 43:S-99transplantation, cyclosporine dosing 43:S-50transplantation, five-year survival 43:S-16, 43:S-22transplantation, growth, long-term follow-up 43:S-56transplantation, growth hormone therapy. 43:S-62, 43:S-65,

43:S-71, 43:S-76transplantation, growth suppression, steroids 43:S-59transplantation, immunizations 43 :S-87transplantation, recurrent disease 43:S-91transplantation, steroid resistant NS (abst) 256transplantation (abst) 1435urinary calcium/creatinine ratios (abst) 1176urolithiasis, metabolic study (abst) 1414urolithiasis (abst) 1455

Chloride removal and AVP action 1235Cholera

ARF, measuring renal injury (abst) 1420IRA complications (abst) 1410

Cholesterol metabolismhepatic, puromycin-induced NS, rats 789LDL uptake, mesangial cells (abst) 248lovastatin, lipid glomerulopathy (abst) 249

Cholesteryl ester transfer protein, proteinuria, LCAT .... 91

Cholinesterase, tubular enzymuria, diabetics (abst) 1396Chondrocalcinosis, renal pathophysiology (abst) 1197Chondrocytes, intermittent/continuous 1 ,25(OH)2D3 708Chronic obstructive lung disease, HD (abst) 1462Chronic renal failure

1 ,25(OH)2D3, cellular immune response (abst) 1403acetylcholine metabolism, brain synaptosomes 630atrial natriuretic peptide, insulin (abst) 910blood glutathione, RBC antioxidation (abst) 1186body composition, HD (abst) 1449calcitriol therapy, renal osteodystrophy (abst) 909carbohydrate metabolism, nifedipine (abst) 1455carbohydrate metabolism, vitamin B6 (abst) 1456care program, Chile (abst) 1424children, EPO therapy, anemia (abst) 911children, GFR determination (abst) 1409children, growth effect of rhGH (abst) 1185children, hyperparathyroidism (abst) 1417children, protein diet (abst) 1417creatinine clearance as GFR marker 1145dyslipidemia, lipoprotein(a), HD (abst) 1187free/protein-bound tryptophan 1366GTT, insulin, blood sugar, GH (abst) 1456HD, survival rate/causes of death (abst) 1186insulin and hypertension (abst) 910lipoprotein(a), post-transplant (abst) 1190mild, cytosolic free sodium (abst) 253morbidity, Cuba (abst) 1456morbidity, elderly (abst) 1456muscle glycogen, glycolytic activity (abst) 1393parathyroid hormone, dietary protein 173plasma endothelin (abst) 916pregnancy (abst) 466, 1469

prevalence, population study (abst) 1457progression, evaluation methods (abst) 1460PTH, calcitriol, 22-OXA-l,25D, Ca transport (abst) ... 467renal arginine synthesis 676rHuEPO effects on Q-EEG, event related potentials.. 1109rHuEPO therapy, anemia, children (abst) 1411

risk factors, population study (abst) 1456slow progression, uric acid, serum phosphorus (abst) . 1436spontaneous decrease PMN cells, HD (abst) 1450

Cimetidine, creatinine clearance, GFR (abst) 1434Cisplatin nephrotoxicity, thyroxine (abst) 1178Cisplatinum, urinary excretion (abst) 251Citrate

aluminum absorption, RF (abst) 253calcium, Tamm-Horsfall protein, COM crystals

(abst) 263urinary excretion, calcium stone formers (abst) 1442

Clinofibrate, APO ratio, uremia, fibric acid 1352Clonidine, Na, water transport, rat CCD 30Clorambucil, prednisone, membranous GN (abst) 1437Cloxacillin, UT! prophylaxis (abst) 1440Coagulation inhibitor, AV fistula clotting (abst) 469Cognitive function, amino acids, HD (abst) 908COL4A5

gene analysis, Alport syndrome (abst) 250mRNA variant splicing, Alport syndrome 1316probe, Alport syndrome (abst) 1183single base insertion, Alport syndrome 1091

Collagen type IIIexpression, in vitro model (abst) 1392glomerulopathy (abst) 250

Collagenase type IV, release from MC, activation(abst) 242

Complement CIQ component, IgG binding, MC (abst).. 1192Complement C4 biosynthesis, IFN-y stimulation 50Complement deficiency

IgA-mediated glomerular inflammation (abst) 1192nephritis, vasculitis 42:S-l3

Computer systemsdiagnosis/management, ARF (abst) 907dialysis prescription (abst) 1490donor-recipient selection process (abst) 1490transplantation (abst) 1491

Congenital nephrotic syndrome, Finnish type 867Congestive heart failure, ibopamine, hemodynamics

(abst) 1196Continuous ambulatory peritoneal dialysis (CAPD)

adequacy, membrane permeability (abst) 1399arterial pressure, peritoneal clearances (abst) 1394atrial natriuretic factor 1465bone densitometry (abst) 1478brain cell function, renal anemia (abst) 911catheter malfunction (abst) 1189catheter migration (abst) 1466catheter (swan neck) insertion (abst) 1403catheter (Tenckhofl) (abst) 919catheter (TWH), complications (abst) 919children, mineral metabolism (abst) 1465children, peritoneal kinetics (abst) 1457CNS function analysis with MEG (abst) 914diabetic nephropathy (abst) 1449dietary protein intake equations 1048exit site/subcutaneous tunnel infections (abst) 915HCV prevalence (abst) 1188HI V-infected patients, outcome 191, 373


hydrostatic-induced transport during 1078IgG concentration in dialysate (abst) 1412KT/V index, clinical outcome (abst) 1188lymphocyte subsets (abst) 1476membrane plasmapheresis, leptospirosis (abst) 1452metabolism, peritoneal equilibration test (abst) 915metabolism, platelet prostanoids (abst) 914multifocal accumulation (abst) 1189nutritional status, assessment (abst) 1412nutritional status, peritoneal transport (abst) 1458nutritional status (abst) 14581,25(OH)2D3, PTH, calcitriol therapy (abst) 1399peritonitis, epidemiology (abst) 914peritonitis, foreign body ileal perforation (abst) 264peritonitis, fungal (abst) 1189peritonitis, gram-negative (abst) 1189peritonitis, inflammatory indicators (abst) 1197peritonitis, intra-peritoneal free elastase 87peritonitis (abst) 919plasma, RBC amino acid profiles (abst) 1188prescription, new method (abst) 1442protein catabolic rate adequacy tests (abst) 464renal osteodystrophy (abst) 910selection criteria (abst) 1427ultrafiltration loss (abst) 914urea kinetic modeling (abst) 260water transport model 700

Continuous arteriovenous hemofiltration (CAVH)ARF, post-CV surgery (abst) 1416pump-assisted venovenous hemofiltration (abst) 1465

Continuous intestinal dialysis (abst) 1188Contrast media

renal artery constriction, ET, prostaglandins 1217RF prevented by theophylline (abst) 251

Converting enzyme inhibitionantiproteinuric effect, dietary protein (abst) 1469protein diet, DM nephropathy (abst) 1454

Coronary heart disease (CHD)nephrotic syndrome and 638pre-transplant screening, diabetics 617

Cortical collecting ductschloride removal, changes in pH, AVP action 1235epithelium, aldosterone, PNA-labeled cells 537epithelium, INF-y regulation, MCP-I 43epithelium composition, embryonic 527K channels, CsA 974Nat, water transport, clonidine 30osmoregulation, hypertonicity 509

Corticosteroidsgrowth suppression, children 43:S-59inhibit TNF-a production, PTEC 352membranous nephropathy, Ponticelli' s schedule

(abst) 1462withdrawal, adults 43:S-26withdrawal, children 43:S-36

Cortisol release, probenecid, PAH-transport, AC (abst).. 238Corynebacterium urealyticum, transplant patients (abst) .. 1496Creatinine

rise without RF, phenacemide (abst) 464tubular secretion, cyclosporine (abst) 1196urinary calcium, children (abst) 1176

Creatinine clearanceas GFR marker, advanced CRF 1145as GFR marker, allografts, CsA (abst) 255as GFR marker, post-transplant (abst) 1434

Creatinine transmembrane transport, phenacemide (abst) .. 464Crescentic nephritis, urine urokinase (abst) 1181

Crystal matrix protein, immunohistochemistry 817Cuprophane membrane

COPD ventilatory function on HD (abst) 1462HD, granulocyte (PMNL) activation (abst) 254

Cyclo-oxygenaseinhibition, hypertension of pregnancy (abst).... 1420, 1457synthesis, smooth muscle cells, CsA (abst) 465

CyclophosphamideFSGS, adults (abst) 1426

intravenous therapy, glomerulonephritis 1492intravenous therapy, lupus nephritis 1470pulse therapy, lupus nephritis (abst) 249pulse therapy, renal function, SLE (abst) 906

Cyclosporin Aacquired cystic kidney disease 613activates Na/H-antiport, VSMC proliferation (abst).... 254acute RF, orthotopic liver transplantation (abst) 254altered body composition metabolism (abst) 261calcium antagonists (abst) 14%children, nephrotic syndrome (abst) 906, 1182creatinine clearance as GFR marker (abst) 255cyclo-oxygenase synthesis, smooth muscle cells

(abst) 465double therapy, azathioprine, steroids (abst) 1443hemodynamic effects (abst) 1481HMGCoA reductase inhibitors (abst) 1438hypertension therapy, Ca antagonists, ACEi (abst) ... 1439

infectious morbidity/mortality (abst) 1473inhibits K channels, cortical collecting tubule 974inhibits TNF-a production, PTEC 352intrarenal deposits, acute rejection (abst) 1402intrarenal deposits, GP-170 expression 1404measurement methods (abst) 1464monotherapy, post-transplant (abst) 14%monotherapy, primary immunosuppression (abst) .... 1491

proteolytic renal cortex enzymes (abst) 254refractory nephrotic syndrome (abst) 1434renal function, post-transplant (abst) 1494steroid resistant nephrotic syndrome (abst) 905toxicity, pediatric nephrotic syndrome (abst) 1182toxicity prevention, using AUC 436toxicity prevention, using Iloprost (abst) 468uricosuric efficacy of benzbromarone (abst) 267

Cyclosporineadult nephrotic syndrome (abst) 1182after triple therapy (abst) 255allograft rupture (abst) 1471with azathioprine, outcome (abst) 1481

children, dosing 43:S-50children, synergistic immunosuppression 43: S- 12lipid metabolism (abst) 255monotherapy, triple therapy, CV risks (abst) 1424non-immunological factors, cadaver grafts (abst) 1418probucol, pharmacokinetic interaction (abst) 1403toxicity reduction, dietary magnesium (abst) 254triple therapy, graft impairment (abst) 1425tubular secretion of creatinine (abst) 11%

Cystic kidney diseaseacquired, cyclosporin A and 613clinical management 42:S-74

Cytokinesexpression, renal cell carcinoma 585IgA nephropathy, abnormal PBMC detection 1298


in situ expression, IgA nephritis 825Cytomegalovirus (CMV)

detection, transplant patients (abst) 256, 1402, 1403gancyclovir therapy (abst) 1496HCV antibodies, HD, post-transplant (abst) 1429immunoprophylaxis, high risk recipients (abst) 266prophylaxis, hypenmmune globulin (abst) 1425

Cytosolic free calcium, MC, protein kinase C (abst).... 1397Cytosolic free sodium, fluorescent dye technique (abst).. 253Cytotoxic antibodies, HD, five-year follow-up (abst) .... 913

D2,8-dihydroxyadenine stone formation (abst) 1198DARPP-32, renal distribution 495Deferoxamine test dosage (abst) 1458Delta of volume, estimating urea (abst) 1417Dermatitis, perforating (abst) 1443Desferioxamine

aluminum clearance (abst) 910Desferroxamine

aluminum removal (abst) 1497osteoblast proliferation (abst) 1497

Dexamethasone, glomerular hypersensitivity (abst) 240Diabetes

apolipoprotein levels, Lp(a), HD (abst) 908HD, risk factors/survival rates (abst) 252intermittent PD versus HD (abst) 1404pre-transpiant screening for CAD 617renal osteodystrophy 159screening, microalbuminuria, proteinuria (abst) 1408serum fructosamine measurement, HD (abst) 908tubular enzymuria, cholinesterase activity (abst) 13%uremia, renal osteodystrophy (abst) 1435

Diabetes mellitusapoliproprotein(a) phenotypes, HD 1062impaired glucose tolerance, post-transplant (abst) .... 1443intralysosomal proteinases, starvation (abst) 248streptozotocin-induced, Ang II receptors (abst) 1392streptozotocin-induced, ANP receptors (abst) 471

Diabetic nephropathyatenolol, captopril, renal function (abst) 1197CAPD (abst) 1449early disease, long-term glycemic control 855HMGCoA reductase inhibitors, hyperlipidemia (abst). 1438lovastatin, prevents GS (abst) 1181mechanisms of glycosaminoglycans (abst) 1395pathogenesis, altered sorbitol mechanisms (abst) 248protein diet, conversion enzyme inhibitors (abst) 1454proteinuria, renal progression (abst) 1181sodium-lithium countertransport, triglycerides 127sodium overload, hypertension (abst) 1428transplantation outcome, age-related (abst) 267

Dialysatebicarbonate, COPD ventilatory function (abst) 1462biocompatibility, bicarbonate buffer, PD (abst) 1394buffers, replacement solution, organic anions (abst)... 1466calcium, mineral metabolism (abst) 265contamination, backtransport (abst) 1423contamination, bacterial endotoxins (abst) 264cooler temperature, hemodynamic stability 606IgG concentration, CAPD (abst) 1412magnesium concentration, erythrocytes, PTH (abst).. 1404plasma volume, isotonic/hypertonic solutions (abst) .. 1415stable/variable sodium, urea excretion (abst) 264types and peritoneal-macrophage functions (abst) 251

Dialysisadequacy, membrane permeability (abst) 1399adequacy, urea kinetic modeling (abst) 260continuous intestinal, mannitol (abst) 1188high risk of cerebral hemorrhage 1086international aid for 479lovastatin, hypercholesterolemia (abst) 1453maintenance, children 43:S-104modality, body composition (abst) 261protein restriction, malnutrition 1139systolic/diastolic cardiac function (abst) 1499urea bounce, incidence of (abst) 1417urea clearance overestimation (abst) 1427

Dialysis-free interval, renal function changes (abst) 1196Dialyzer sterilization with polyvinylpyrrilidone (abst)... 1409Diarrhea, electrolyte changes with (abst) 1176Dietary

fish oil, increase of GS (abst) 248magnesium, cyclosporine nephrotoxicity (abst) 254phosphorous, hyperparathyroidism (abst) 1428protein, Ang II, catecholamines 285protein, angiotensin inhibitors, NS (abst) 1415protein, CE!, diabetic nephropathy (abst) 1454protein, CRF, children (abst) 1417protein, excretion lithogenic substances (abst) 1418protein, excretion urinary oxalate, glycolate 366protein, intake equations, CAPD 1048protein, lipid metabolism, NS (abst) 1415protein, muscle metabolism, amino acids (abst) 465protein, parathyroid hormone, CRF 173protein, renal failure, IGF-!, PTH (abst) 262protein, renal function, rats (abst) 1456protein, renal vasodilation 659protein, uninephrectomy, renal injury (abst) 1454protein restriction, malnutrition 1139

Digital subtraction renal angiography (abst) 1449Disasters, international dialysis aid 479Distal renal tubular acidosis, lithiasis (abst) 1418Diuretics

furosemide type, Na/K cotransport system (abst) 237renovascular hypertension, urinary ACE (abst) 1420

DNA repair in uremia 385Donors, renal

cadaver grafts, in children 43:S-99cadaver grafts, long-term function (abst) 1439cadaver grafts, survival rates (abst) 1405, 1418cadaver grafts, Third World (abst) 1420computer systems (abst) 1490living related, attitudes of 262living unrelated (abst) 1398organ exchange, HLA matching (abst) 1480same donor, effect on prognosis (abst) 1472

DopaminecAMP-dependent phosphoprotein, renal effects 495indomethacin reverses renal effects (abst) 1411

Doppler sonographycolor evaluation, post-transplant (abst) 466detection of transplant rejection (abst) 256echo pulsatility index, renal artery stenosis (abst) . . . . 1393transcranial diagnosis, brain death (abst) 1459

Double-lumen vascular access catheterinsertion, ventricular arrhythmias (abst) 1481

Double-lumen vascular access catheter (abst) . . . . 1414, 1443Dry weight

estimation parameters (abst) 252


non-invasive blood volume monitoring 851Dual-X-ray absorptiometry, body composition (abst) .... 261Dyslipidemia

lipoprotein(a), CRF, HD (abst) 1187treated essential hypertension, racial aspects (abst). . . 1407

Dysplicemia, CAPD (abst) 1471

EEcho-doppler pulsatility index (abst) 1393Echographic study, parathyroid glands, HD (abst) 1438Edema (ankle), nifedipine, sodium retention (abst) 1194Elastinoly-tic enzyme, ANCA, proteinase 3 (abst) 1194Elderly

ARF, progressive glomerulonephritis (abst) 1486CRF morbidity (abst) 1456

Electroencephalography, quantitative, rHuEPO, CRF .. 1109ELISA immunoblotting method, lupus antibodies (abst). 1475Embolization, rejected allograft, absolute ethanol (abst). 1468Enalapril

hypertension, immunosuppression (abst) 1439reduces hematocrit elevation (abst) 1477

End-stage renal disease (ESRD)adequacy of dialysis (abst) 260bone histology, vitamin D3, PTH, radiology 1071cardiac gated blood pool scan (abst) 1186dialysis modality, body composition (abst) 261erythropoietin concentration, HD (abst) 1185HIV infection, survival and CAPD 373platelet fibrinogen receptor function (abst) 252reactive perforating collagenosis (abst) 1405

Endocarditisbacterial, ON, antibiotic therapy (abst) 469enterococcus bacteremia (abst) 1418

Endocrine function, EPO therapy, HD (abst) 912Endopeptidases, kinase activity localized (abst) 1420Endothelial cells, adhesion molecules, leukocytes ... 42:S-27Endothelial nitric oxide synthase expression, EC, MC

(abst) 1489Endothelin (ET)

basal vascular tone control (abst) 239EDRF, role in renal microcirculation (abst) 1393lupus nephntis (abst) 1185renal actions, Nephrology Forum 451renal hemodynamics, rabbits (abst) 263rHuEPO therapy, CRF (abst) 1478

Endothelin (ET)-1administration, renal function (abst) 263renal handling, essential hypertension (abst) 1400

Endothelin (ET)-3, renal localization using PCR 1273Endothelin (ET) antagonist

progressive renal disease 440reverses renal vasoconstriction 1217

Endothelin (ET) receptorsnuclear protein kinase C, renal cell nuclei (abst) 239porcine inner medullary collecting duct cells (abst). . . . 239subtypes, new ligands 36

Endothelium-derived relaxing factor (EDRF)basal vascular tone control (abst) 239endothelin, renal microcirculation (abst) 1393pressure control of renin release (abst) 240renal vasoconstriction, endotoxemic rats (abst) 1194

Endotoxinsbacterial contamination, dialysate (abst) 264shock, EDRF, renal vasoconstriction (abst) 1194TNF-a, IL-6, uremia (abst) 1392

Enlaparil, nephrosclerosis therapy (abst) 245Enterococcus bacteremia, endocarditis (abst) 1418EP3 receptor, in situ hybridization 1372Epiphyseal impaction, post-transplant 98Epithelial cells, embryonic composition, CCD 527Erythrocytes, dialysate magnesium, PTH (abst) 1404Erythrocytic dysmorphism, aluminemia (abst) 1400Erythrocytic membranes, liquorice abuse (abst) 1400Erythrocytosis, theophylline, post-transplant (abst) 918Erythropoiesis

aluminum, progenitor cell activity (abst) 1463aluminum, renal failure (abst) 1463

Erythropoietinanemia, CRF, children (abst) 911concentration, ESRD, HD (abst) 1185deficit, anemia, ARF (abst) 1411histamine release, HD patients (abst) 1394increased thrombosis risk, HD 182low-dose, intravenous iron, anemia, HD (abst) 911molecular biology, Nephrology Forum 887NECA effects on production 734polycythemia, nitric oxide, RBF 430renal cell production, identified 1149renal formation, hypoxic hypoxia (abst) 238serum levels, post-transplant (abst) 1433thyroid hormones stimulate production (abst) 238

Erythropoietin therapyadministration routes, HD (abst) 1413, 1480anemia, HD (abst) 912anemia, RF, cardiovascular aspects 1309anemia, uremia, not on dialysis (abst) 1434arterial pressure (abst) 1482autologous blood transfusion (abst) 469/3-glycosylated, HD (abst) 912bone marrow changes, HD (abst) 1185CAPD, HD (abst) 1479endocrine function, HD (abst) 912hematocrit, BP (abst) 1478hypophisial-gonadal axis (abst) 1475improves quality of life, HD (abst) 1412, 1413iron absorption, aluminum intoxication (abst) 1467pre-dialysis, CRF (abst) 1475pulmonary function changes (abst) 1469transplantation (abst) 1478

Essential hypertensioncompared, hypertension of NIDDM (abst) 1419cytosolic free sodium, platelets (abst) 244dyslipidemia, racial aspects (abst) 1407insulin resistance, LVH (abst) 1490microalbuminuria, antihypertensives (abst) 246nitrendipine (abst) 1469obesity, CV risk (abst) 1419renal handling of El-I (abst) 1400

European (EDTA-ERA) Registry data 43:S-22Event-related potentials on Q-EEG, rHuEPO effects ... 1109Exercise capacity, rHuEPO therapy, CRF, HD (abst) .. 1416Extracellular matrix

altered synthesis in membranous nephropathy (abst)... 247glycoprotein expression, ADPKD (abst) 243

F5 '-N-ethylcarboxamideadenosine (NECA) 734Fabry's disease (abst) 1183Familial Mediterranean fever 834Familiar hypercholesterolemia (abst) 916


Fe-gluconate therapy, iron deficiency (abst) 1421Femoral arteriovenous fistula

post-vascular puncture for HD (abst) 470Femoral catheters, vascular access, HD (abst) 470Fibric acid, APO ratio in uremia, clinofibrate 1352Fibrillary GN, without renal immunoglobulin deposits... 837Fibrinolysis

glomerular, anti-GBM nephritis 557hemolytic uremic syndrome (abst) 1195platelet activation, dialysis membrane (abst) 1187

Fish oil, dietaryincrease of glomerulosclerosis (abst) 248lupus nephritis, clinical findings 75

FK506, inhibits TNF-a production, PTEC 352Flow cytometry

cross match (abst) 1393platelet function in uremia (abst) 1484

Fluorescent dye technique (abst) 253Focal contact formation, integrin PCR expression, MC .. 997Focal segmental glomeruloscierosis (FSGS)

adults, cyclophosphamide (abst) 1426children, nephrotic, follow-up (abst) 1182children, post-transplant 43:S-91children (abst) 1426glomerular hypertrophy, rats (abst) 247integrin expression in podocytes (abst) 247minimal change disease, renal biopsy (abst) 905transplantation (abst) 1487

Food intake, hemodynamic response (abst) 1447Free oxygen radicals, induced by metals, HD (abst).. .. 1437Free radical production, age, HD (abst) 1483Fructosamine measurement, diabetics, HD (abst) 908Fungal peritonitis

Candida, PD (abst) 1452CAPD (abst) 1189chronic PD (abst) 468

FurosemideNa/K cotransport system (abst) 237oliguric ARF (abst) 1451

Gy-melanocyte stimulating hormone (abst) 472Gancyclovir therapy, CMV infection (abst) 14%Gastrointestinal tract perforations (abst) 913Gated blood pool scan, cardiac, ESRD (abst) 1186Gelatinase release, MC activation by plasmin (abst) 242Gemfibrozil, hyperlipidemia, uremia, HD (abst) 1419Gene expression, renal 42:S-47Gene transfer, mammalian kidney (abst) 1419Gentamicin toxicity

interstitial cell infiltrate (abst) 1450in vitro model 13

Gestational hypertension (abst) 1420Glomerular angiotensinase A, regulation (abst) 244Glomerular basement membrane, heparan sulfate

proteoglycan (abst) 1192Glomerular disease, n-3 fatty acids, proteinuria 843Glomerular endothelial cell function, integrin receptors .. 278Glomerular epithelial cells

ATP analogues, UTP activate phospholipase C (abst).. 258lipoprotein uptake, nephrotic syndrome 1341

Glomerular fibrinolytic activity, anti-GBM GN 557Glomerular filtration rate (GFR)

99mTcDTpA assessment (abst) 1190creatinine clearance as marker 1145

creatinine clearance as marker (abst) 255, 1434determination methods, children (abst) 1409k x body weight/P creatinine formula (abst) 259measurement by "single-shot" inulin (abst) 1195renal amino acid infusion, glucagon (abst) 1413

Glomerular hypertrophy, FSGS (abst) 247Glomerular immune deposits, anti-DNA monoclonal

antibodies (abst) 905Glomerular injury

modulated by IL-6 967TGF-/3l induces MC hypertrophy 948

Glomerular peripolar cell 42:S-35Glomerulo-tubular feedback mechanism

adenosine, TAL cells and (abst) 239loop diuretics (abst) 237

GlomerulonephritisANCA-associated (abst) 1184ATS-induced, MCP- 1 expression 1036bacterial endocarditis, antibiotic therapy (abst) 469epidemiology, Spain (abst) 1495fibrillary, without renal immunoglobulin deposits 837hepatitis B virus (abst) 1184, 1185HIV-associated 1327HMC proliferation, role of IL-6 (abst) 2411gM mesangial proliferative (abst) 1404immune complex-mediated, platelet clearance 716mesangial matrix metalloproteinases (abst) 258microscopic urinalysis 42:S-9pathogenesis 42:S-19primary, clinical study (abst) 1451Priscilla Kincaid-Smith, contributions of 42:S-2progressive, ARF, elderly (abst) 1486rat model 294recurrent, post-transplant (abst) 257Wegener's granulomatosis (abst) 1183

Glomerulopathyallograft 42:S-104allograft, children 43:S-95collagen type III (abst) 250lipid, lovastatin, cholesterol levels (abst) 249lisinopril, microalbuminuria, proteinuria (abst) 1407morphologic analysis, post-transplant (abst) 1406schistosomalschistosomal mansoni (abst) 1426transplant, incidence/evolution (abst) 1439

Glomerulopathy primary, clinical pathology (abst) 1431Glomeruloscierosis

antihypertensive agents, ACEI, Ca antagonist (abst).. 1178induced by fish oil diet (abst) 248lovastatin, diabetic glomerulopathy (abst) 1181nodular, heavy/light chain deposits (abst) 471ovariectomy, triglycerides, analbuminemia (abst) 1193TGF-f3l, MC hypertrophy 948

GlucocorticoidsAddison's, panhypopituitarism 1130Addison's, panhypopituitarism (abst) 1196body composition, metabolism, post-transplant (abst).. 261deficiency, phospholipase (abst) 263

Gluconic acid as glucose substitute, PD (abst) 1394Glucose elevation, calcium ion uptake, VSMC 344Glucose modulates ANP, Ang H actions, MC 518Glucose tolerance, DM, post-transplant (abst) 1443Glucose tolerance (GIT) test, insulin, GH, CRF (abst). . 1456Glutathione levels, RBC antioxidant activity (abst) 1186Glycolate excretion, urinary oxalate, protein intake 366


Glycolipid blood group antigens, renal expression 1289Glycolytic activity, muscle glycogen, CRF (abst) 1393Glycoprotein expression, intrarenal CsA deposits (abst). 1404Glycosaminoglycans, diabetic nephropathy (abst) 1395Goodpasture' s syndrome

azathioprine hypersensitivity (abst) 261HLA-DR and -DQ types 307therapeutic immunoadsorption (abst) 1427

GP-170 expression, intrarenal CsA deposits (abst) 1404Granulocyte inhibitory protein, HD, 2m (abst) 253Granulocyte-macrophage colony stimulating factor

(abst) 1191Granulocyte (PMNL) activation, HD (abst) 254Grey level granulometry, renal damage (abst) 1450Growth, post-transplant children 43:S-56Growth factors, renal, PTC cultures (abst) 1443Growth hormone

children, CRF (abst) 1185gene expression, acidosis 1224post-GTF, insulin, blood sugar, CRF (abst) 1456puromycin aminonucleoside nephropathy 1281renotropic effects with rhIGF-1 1251

Growth hormone therapychildren, post-transplant. 43:S-62, 43:S-65, 43:S-71, 43:S-76children with allografts 199

Guillain-Barré syndrome (abst) 1443

HHantavirus

hemorrhagic fever with renal syndrome (abst) 1180isolated, Korean hemorrhagic fever (abst) 1179

Haploidentical recipients, transfusions (abst) 1435Heat stress syndrome, neonatal (abst) 1179Heavy chain deposits, nodular GS (abst) 471Hematocnt

blood pressure, EPO therapy (abst) 1478elevations, enalapnl (abst) 1477rHuEPO therapy, anemia (abst) 1441

Hematuria, relapsing (abst) 1464Hemodiafiltration (abst) 1415Hemodialysis

35°-C dialysate, hemodynamic stability 606A-V fistula hemodynamics (abst) 1465acquired cystic kidney disease (abst) 1412acute phase reactans C3a, /32m (abst) 1437adequacy, KT/V index, blood urea levels (abst) 916adequacy, percentage reduction, urea (abst) 1436albumin-free rHuEPO, CRF (abst) 1413allergic reactions (abst) 1414, 1422amino acids, cognitive function (abst) 908amyloidosis (abst) 1395, 1409, 1461anemia, EPO therapy (abst) 911, 912angiotensin converting enzyme (abst) 1437apolipoprotein levels, Lp(a), diabetics (abst) 908apoliproprotein(a) phenotypes, with/without DM 1062blood volume and dry weight 851body composition, CRF (abst) 1449bone loss, hyperparathyroidism (abst) 253bone mineral density, transplantation (abst) 1457calcitriol therapy, hyperparathyroidism (abst) 1408calcitriol therapy, osteocalcin levels (abst) 1408calcitriol therapy, risks/benefits (abst) 259calcitriol therapy (abst) 1455chronic, bacteremia, multicenter study (abst) 467CNS function analysis with MEG (abst) 914

COPD, ventilatory function (abst) 1462CRF, survival rate/causes of death (abst) 1186desferioxamine, aluminum clearance (abst) 910diabetic patients, survival rates (abst) 252dialysis time, females/males (abst) 1484double lumen catheter, urea kinetics (abst) 1443

dyslipidemia, lipoprotein(a), CRF (abst) 1187echographic study, parathyroid glands (abst) 1438endocrine function, EPO therapy (abst) 912EPO, histamine release (abst) 1394EPO concentration, ESRD (abst) 1185EPO therapy, aluminum intoxication (abst) 1467EPO therapy, quality of life (abst) 1412, 1413EPO therapy, thrombosis risk 182EPO therapy (abst) 1413erythrocytic dysmorphism, aluminemia, uremia

(abst) 1400exercise capacity, rHuEPO therapy (abst) 1416fistula survival factors (abst) 1187free oxygen radicals, induced by metals (abst) 1437free radical production, age (abst) 1483HBV prevalence (abst) 1432HBV vaccination (abst) 1425HCV, CMV, post-transplant (abst) 1429HCV, hepatic histopathology (abst) 1445HCV (abst) 1407, 1410HCV antibodies (abst) 1410HCV detection, pre-transpiant 1097HCV detection by PCR (abst) 464HCV genome in serum (abst) 1391HCV prevalence, patients/personnel (abst) 1418HCV prevalence, risk factors 1322HCV prevalence (abst) 1188, 1402, 1405, 1423, 1432HCV transmission (abst) 1467hepatitis antibody prevalence (abst) 917hypercalcemia, hyperparathyroidism (abst) 1405hyperlipidemia, gemfibrozil treatment (abst) 1419hyperphosphatemia treatment (abst) 260hypotension, NO, uremia, platelet dysfunction 445immunological function, calcitriol (abst) 1398induction of IL-I, TNF, IL-6 (abst) 1187INF-a-2C treatment, HIV carriers (abst) 1399influenza vaccination (abst) 918versus intermittent PD, diabetes (abst) 1404iron deficiency, Fe-gluconate therapy (abst) 1421L-carnitine, vascular refilling, ultrafiltration (abst) 260lipid abnormalities, transplantation, uremia (abst) .... 1441

lipid metabolism (abst) 1406long-term changes in tumor markers (abst) 917mannitol use, osmolar gap as evaluation (abst) 1422mechanisms of polydipsia 107microdialysis measures urea kinetics 622mineral metabolism, calcium dialysate (abst) 265non-occlusive ischemic ileitis (abst) 1444nutritional status (abst) 1459patient rehabilitation (abst) 1431phagocytosis inhibition 208plasma volume, isotonic/hypertonic solutions (abst) .. 1415plasmic compounds of low molecular weight (abst)... 1437prescription, computer systems (abst) 1490procollagen I C-terminal peptide (abst) 13%protein/caloric malnutrition, PCR, HD (abst) 1467pruritus (abst) 1483rapid, high efficiency (abst) 917renal osteodystrophy (abst) 910


serological markers, uremic pruritus (abst) 1467serum albumin as mortality predictor 115serum fructosamine measurement, diabetics (abst) . . . . 908short, hemodynamic tolerance (abst) 1471silent myocardial ischemia (abst) 1411spontaneous decrease PMN cells, CRF (abst) 1450stool parasites (abst) 1471T cell activation defect, B7/CD28 pathway 359ten-year follow-up, Uruguay (abst) 1459, 1460twelve-year follow-up, Chile (abst) 1419vessel wall properties, normotensive patients (abst) . . . 252

Hemodynamicsbody position (abst) 1446cyclosporine A (abst) 1481food intake (abst) 1447ibopamine, CHF (abst) 1196opening/closing A-V fistula (abst) 1465

Hemofiltrationcontinuous arteriovenous (abst) 1416continuous venovenous 1465

Hemoglobin estimation, rHuEPO therapy, anemia(abst) 1441

Hemolytic uremic syndrome (HUS)children, post-transplant 43:S-91fibrinolytic system (abst) 1195

Hemoperfusionacute exogenous intoxications (abst) 1453desferioxamine, aluminum clearance (abst) 910

Hemophane membrane, granulocyte activation (abst).... 254Hemorrhagic fever with renal syndrome (HFRS)

cytokines for proteinuria (abst) 1180hantavirus partial RNA isolation (abst) 1179monoclonal antibody development (abst) 1180T-cell subsets, flow cytometry (abst) 1180transendothelial migration, mononuclear cells (abst) .. 1180

Henle's loop, lithium transport simulation 337Henoch-SchOnlein nephritis (abst) 1183Heparan sulfate proteoglycan (HSPG)

molecular cloning from GBM (abst) 1192renal hemodynamics, proteinuria (abst) 1192

Heparin, low molecular weight, single bolus (abst) 1477Hepatitis B virus (HBV)

clinical course, post-transplant (abst) 1189glomerulonephritis, ACEi effect (abst) 1184glomerulonephritis, a-IFN therapy (abst) 1184glomerulonephritis, compared SLE (abst) 1185hepatic dysfunction, HBsAg analysis (abst) 1448immunization after rHuEPO therapy (abst) 1430prevalence, HD (abst) 917prevalence, HD/transplantation (abst) 1432reactivation with immunosuppression (abst) 1427vaccination, post-transfusion immunization (abst).... 1425

Hepatitis C virus (HCV)antibodies, HD (abst) 1485, 1488, 1491antibodies, transplantation (abst) 1495clinical course, post-transplant (abst) 1189CMV antibodies, HD, post-transplant (abst) 1429detection, pre-transplantation, HD 1097detection by PCR, hemodialysis (abst) 464epidemiology, transmission, HD (abst) 1467hemodialysis (abst) 1410hepatic dysfunction, HBsAg analysis (abst) 1448hepatic histopathology, HD (abst) 1445hepatic lesions, dialysis-acquired (abst) 1496impact, chronic HD (abst) 1407

predialysis, epidemiology (abst) 1467prevalence, HD 1322prevalence, HD, CAPD (abst) 1188prevalence, HD, transplantation (abst) 1432prevalence, HD (abst) .. 917, 1188, 1402, 1405, 1418, 1423,

1433, 1448, 1475, 1492prevalence, personnel (abst) 917, 1418, 1492prevalence, post-transplant (abst) 914RNA genome in HCV transplant patients (abst) 1391

Hepatitis D virus, prevalence, HD (abst) 917Heymann nephritis (abst) 472Hippuran, renal extraction, ACEi, rats (abst) 1194Histamine release, HD, EPO (abst) 1394HLA antigens

polyarteritis, renal involvement (abst) 906HLA-antigens

tumor necrosis factor-a 1486HLA-DR and -DQ types in anti-GBM nephritis 307HLA-identical transplant recipients, OKT3 (abst) 468HLA matching, effect on graft survival (abst) 1190HMG-CoA reductase inhibitors

hypercholesterolemia, dialysis (abst) 1453hypercholesterolemia, post-transplant CsA (abst) .... 1438hyperlipidemia, diabetic nephropathy (abst) 1438

Honeybees, African and ARF (abst) 1455Human immunodeficiency virus (HIV)

CAPD outcome and 191, 373immune-complex glomerulonephritis 1327INF-a-2C treatment, HD (abst) 1399MC expression increased by TGF-/3 191

prevention, autologous transfusion (abst) 469renal lesions (abst) 466TGF-/3, genetic expression in MC 1022

Humoral control, medullary blood flow (abst) 239Hydrostatic-induced transport during CAPD 1078Hydroxyvitamin D3, renal osteodystrophy, HD (abst) ... 910Hypercalcemia, hyperparathyroidism, HD (abst) 1405Hypercalciuria

calcium depletion, overload test (abst) 1493calcium stone formers, PTH, calcitonin (abst) 1397children, bone mineral density (abst) 1176, 1421urinary sodium/creatinine, nephrolithiasis (abst) 1445

Hyperchloremic acidosis, transplantation (abst) 1397Hypercholesterolemia

HMGCoA reductase inhibitors, CsA (abst) 1438lovastatin, dialysis (abst) 1453simvastatin, nephrosis, proteinuria 1124simvastatin, rejection (abst) 1497

Hyperimmune globulin, CMV prophylaxis (abst) 1425Hyperkalemia

acute, control with nebufized salbutamol (abst) 1412risk factors, prognosis (abst) 908

Hyperlipidemiagemfibrozil treatment, uremia, HD (abst) 1419HMGCoA reductase inhibitors, DM nephropathy

(abst) 1438lovastatin, nephrotic proteinuria (abst) 1429

Hyperoxaluria, children, post-transplant 43:S-91Hyperparathyroidism

1-a hydroxyvitamin D3, HD (abst) 141122-oxa-calcitriol, calcium metabolism 551bone densitometry (abst) 1485calcitriol therapy, chronic HD (abst) 1408children, CRF (abst) 1417experimental PTH response, 1 ,25(OH)2D3 1259


high phosphorus diet (abst) 1428hypercalcemia, HD patients (abst) 1405oral calcitriol pulse therapy (abst) 253prevents bone loss, long-term HD (abst) 253T cell immunity, 1 ,25(OH)2D3, uremia (abst) 1391

Hyperphosphatemia, aluminum hydroxide therapy (abst)... 260Hyperprostaglandin E-syndrome, Tamm-Horsfall

protein 401Hypertension

adrenal masses (abst) 1473adrenal microadenomas, aldosterone (abst) 916ambulatory blood pressure monitoring (abst) .. . 1444, 1481arterial, adolescents (abst) 1477calcium antagonists, ACEi, immunosuppression

(abst) 1439cytosolic free sodium, platelets (abst) 244diabetic, compared, essential hypertension (abst) .... 1419

dialysis, antihypertensives, regression of uremicLVH 881

drug treatment 42:S-68hemodynainic response, body position (abst) 1446hemodynamic response, food intake (abst) 1447incidence, children (abst) 1407insulin, CRF (abst) 910insulin resistance, hyperinsulinemia (abst) 1395intracellular calcium pools, VSMC (abst) 244isolated systolic, antihypertensive agents (abst) 911malignant, clinical study (abst) 1177malignant, enzymatic profile analysis (abst) 1428management, post-transplant 43:S-45plasma endothelin concentration (abst) 1178pregnancy (abst) 1420, 1436, 1457Priscilla Kincaid-Smith, contributions of.. 42:S-50, 42:S-52renal angiography (abst) 1449renal functional consequences 42:S-52renin profiling, Nephrology Forum 1163renovascular, ACE (abst) 245renovascular, ACEi, Nephrology Forum 1379renovascular, control post-PTA (abst) 911renovascular, diagnostic tests (abst) 1448renovascular, treatment (abst) 1416renovascular, urinary ACE, diuretics (abst) 1420unilateral small kidney (abst) 1449"white coat" (abst) 1444

Hypertonicity, osmoregulation, collecting duct cells 509Hypertriglyceridemia, fibric acid, clinofibrate 1352Hyperuricemia, benziodarone, transplantation (abst).... 1480Hypocitraturia, calcium stone formers (abst) 1442Hypokalemia, familial renal pathophysiology (abst) 1197Hypomagnesemia, familial renal pathophysiology (abst). 1197Hyponatremia, neurologic complications (abst) 471Hypophisial-gonadal axis, CRF, EPO therapy (abst).... 1475Hypophosphatemia, post-transplant (abst) 1483Hypothyroidism, thyroxin, renal function (abst) 1195Hypoxic hypoxia, EPO-producing cells (abst) 238Hyroxine, cisplatin-nephrotoxicity (abst) 1178

IIbopamine, hemodynamic effects, CHF (abst) 1196Idiopathic IgA nephropathy, IL-4, IL-6 (abst) 1489Idiopathic membranous nephropathy (abst) 1424IFN-y-activation, lupus nephntis (abst) 1441IgA, IgG2a anti-CD3 isotype switch variants (abst) 1198IgA nephropathy

children, post-transplant 43:S-91

cytokine networks, abnormal PBMC detection 1298glomerular inflammation, complement depletion (abst).. 1192idiopathic, IL-4, IL-6 (abst) 1489renal function, Na-lithium countertransport (abst) 906shared idiotypes, mesangial deposits 65in situ cytokine expression 825

IgE, HD and hypersensitivity (abst) 1475IgG

binding, to C1Q complement subunit, MC (abst) 1192binding, to Tamm-Horsfall protein 1014concentration, dialysate, CAPD (abst) 1412incidence of peritonitis (abst) 1476

IgG2a, IgA anti-CD3 isotype switch variants (abst) 11981gM mesangial proliferative glomerulonephritis (abst)... 1404Ileitis, non-occlusive ischemic, HD (abst) 1444Ileum, foreign body perforation, CAPD (abst) 264Iloprost, CsA glomerular vasoconstriction (abst) 468Immune complex-mediated GN, platelet clearance 716Immunizations, pediatric transplant patients 43:S-87Immunoallergic ARF, children, NSAIDs (abst) 467Immunologic function

antigen presentation, parenchymal cells 927cellular response, 1 ,25(OH)2D3, CRF (abst) 1403HD, uremia, calcitriol therapy (abst) 1398

Immunosuppressionaluminum intoxication (abst) 1453children, synergistic regimens, cyclosporine 43:S-12comparison studies (abst) 1488hepatitis B reactivation (abst) 1427hypertension, Ca antagonists, ACEi (abst) 1439hyporesponsiveness (abst) 1489infections, post-transplant (abst) 914neutrophil chemotaxis (abst) 1400OKT3, ATG-Fresenius, post-transplant (abst) 266OKT3, HLA.identical recipients (abst) 4fisteroids, azathioprine, CsA (abst) 1443

Indomethacin reverses renal effects, dopamine (abst)... 1411Infants, urinary concentration, asphyxia (abst) 1457Infections

exit site/subcutaneous tunnel, CAPD (abst) 915morbidity/mortality decrease, CsA (abst) 1473post-transplant, Nephrology Forum 221with triple immunotherapy, post-transplant (abst) 914vascular access, post-stent insertion (abst) 470

Influenza vaccination post-transplant, HD (abst) 918Infusion clearance, inulin 1058Inherited kidney disorders, molecular approach 1205Injury

glomerular, modulated by IL-6 967glomerular, TGF-/31, MC hypertrophy 948renal, cholera, ARF (abst) 1420

Inner medullary collecting duct cells, ET-lR (abst) 239Insulin

atrial natriuretic peptide, CRF (abst) 910hypertension, CRF (abst) 910post-GTT, GH, CRF (abst) 1456

Insulin-dependent diabetes mellitusaluminum, non-diabetic uremia (abst) 1445histomorphometric bone pattern, dialysis (abst) 1445tubular enzymuria, cholinesterase activity (abst) 1396

Insulin-like growth factor-IPTH, RF induced by protein diet (abst) 262renotropic effects with rhGF 1251

Insulin-like growth factor-I receptor 1242Insulin receptor, gene expression (abst) 1395


Insulin resistanceNa retention, NIDD 139salt sensitivity (abst) 246

Integrin expression, focal contact formation, MC 997Integrin receptors, glomerular endothelial cells 278Intercellular adhesion molecule- 1 (abst) 1442Interferon-a-2C, HIV carriers, HD (abst) 1399Interferon-y

regulation, MCP-l in cortical epithelial cells 43stimulation, C4 biosynthesis, tubular cells 50

Interleukin-1 (IL-I)induction, dialysis membrane effect (abst) 1187mediated expression of MnSOD, mechanisms (abst)... 242PBMC production, dialysis membrane effect (abst)... 1187

Interleukin-2, T cell expression, I ,25(OH)2D3 (abst) 909Interleukin-2 receptor (IL2R)

dialysis amyloidosis, uremia (abst) 1395expression, antisense oligonucleotides (abst) 255expression, PD (abst) 1473expression, rejecting allograft (abst) 255minimal change NS, children (abst) 1182

Interleukin-4 (IL-4)idiopathic IgA nephropathy (abst) 1489minimal change NS, children (abst) 1182

Interleukin-6 (IL-6)diagnostic value, post-transplantation (abst) 256down-regulated production (abst) 254expression, renal cell carcinoma 585idiopathic IgA nephropathy (abst) 1489induction, dialysis membrane effect (abst) 1187mesangial cell growth regulation (abst) 241modulates glomerular injury 967PBMC production, dialysis membrane effect (abst)... 1187TNF-a, HD (abst) 1495TNF-a, release by monocytes, uremia (abst) 1392

International dialysis aid 479Interstitial cell infiltrate, gentamicin (abst) 1450Interstitial chronic renal injury (abst) 1450Interstitial fibrosis in obstructive nephropathy 774Interstitial tubule disease (abst) 1451Intoxications, acute exogenous, hemoperfusion (abst)... 1453Intra-peritoneal free elastase, CAPD peritonitis 87Intralysosomal proteinases, DM nephropathy (abst) 248Intraperitoneal transport, hydrostatic pressure, CAPD.. 1078Intrarenal pressure determination, RF, post-transplant

(abst) 1421Inulin

renal versus infusion clearance 1058"single-shot" injection, GFR measurement (abst) 1195

Iron, calcium, oxidant-induced DNA damage 1228Iron therapy

EPO therapy, aluminum intoxication (abst) 1467EPO therapy, HD (abst) 911Fe-gluconate, HD (abst) 1421rFIuEPO, dialysis (abst) 1476

lschemia, renal warm (abst) 1428Ischemic non-occlusive ileitis, HD (abst) 1444Isradipine, arterial BP, renal hemodynamics (abst) 1429

JJuxtamedullary arterioles, neural control 684

KK channels

ANF, Ang II, adenosine glomerular responses (abst) .. 240

inhibition of, ammonium, depolarized TAL cells(abst) 237

inhibition of, CsA 974oscillations, migrating MDCK cells (abst) 237

K ions, arterial pressure changes (abst) 908Kallikrein-kinin system, potassium loading (abst) 1454Kaposi's sarcoma, transplantation (abst) 918Karyomegalic interstitial nephritis (abst) 259Ketotifeno, pruntus treatment (abst) 1415Kincaid-Smith, Priscilla ... 42:S-2, 42:S-50, 42:S-52, 42:S-71,

42:S-99Korean hemorrhagic fever (abst) 1179, 1180KT/V index

blood urea levels, CAPD outcome (abst) 1188blood urea levels, HD adequacy (abst) 916

LL-carnitine, vascular refilling, ultrafiltration (abst) 260Laparoscopic renal surgery 273Laxative-induced diarrhea, electrolyte changes (abst). . . 1176Lead nephropathy (abst) 1486, 1487Lecithin :cholesterol acyltransferase, proteinuria, CETP. . . 91Left ventricular hypertrophy

antihypertensive therapy 881essential hypertension (abst) 1490

Leptospirosis, membrane plasmapheresis, CAPD (abst). 1452Leukocyte-endothelial cell adhesion molecules 42:S-27Leukocytes, peripheral blood, PMMA membrane (abst). 1394Leukopenia

azathioprine, GM-CSF (abst) 1191treatment (abst) 1479

Ligands, El receptor subtypes 36Light chain deposits, nodular GS (abst) 471Lipid levels

abnormalities, transplantation, uremia (abst) 1441immunosuppression, post-transplant (abst) 1198post-pancreas/renal transplant (abst) 266

Lipid metabolismbody composition, CsA, carbohydrates (abst) 261chronic hemodialysis (abst) 1406nephrotic syndrome, dietary protein (abst) 1415transplantation (abst) 1474

Lipo-oxygenase inhibitorshypertension of pregnancy (abst) 1420, 1457

Lipoprotein uptake, glomerular EC, nephroticsyndrome 1341

Lipoprotein(a)apolipoprotein levels, diabetics, HD (abst) 908concentration, CRF, post-transplant (abst) 1190dyslipidemia, CRF, HD (abst) 1187nephrotic syndrome 1116nephrotic syndrome (abst) 1182

Liquorice abuse (abst) 1400Lisinopril, microalbuminuria, BP, glomerulopathy

(abst) 1407Lithiasis, renal acidification capacity (abst) 1418Lithium nephrotoxicity 42:S-93Lithium-sodium countertransport, DM nephropathy 127Lithium transport simulation, thin ioop segments 337Liver transplantation

acute renal failure (abst) 1499CsA, ARF (abst) 254

LLC-PKI cells, oxidant-induced DNA damage 1228Lovastatin

glomerulosclerosis, diabetic nephropathy (abst) 1181


hypercholesterolemia, CsA (abst) 1438hypercholesterolemia, dialysis (abst) 1453hyperlipidemia, nephrotic proteinuria (abst) 1429lipid glomerulopathy, cholesterol levels (abst) 249

Low density lipoproteins (LDL)APO B epitopes, HD 1360MC uptake, cholesterol metabolism (abst) 248

Lower limb paraplegia, metabolic study (abst) 1446LPS modifies plasminogen activator/plasmin (abst) 258Luminal cGMP decreases Cl flux in the mTAL 741Lupus nephritis

ANCA-associated (abst) 1185children, post-transplant 43:S-9lclinical/pathologic features, males (abst) 1184clinical study (abst) 1184cyclophosphamide therapy (abst) 249, 1470, 1492endothelin role (abst) 1185fish oil, clinical findings 75IFN-y-activation, EC, immune response (abst) 1441reversibility of RF (abst) 1488risk factors, treatment (abst) 1461T cell clones, renal involvement in SLE (abst) 1441

Lupus nephropathyantibodies, ELISA measurement (abst) 1475antiphospholipid antibodies (abst) 1489renal biopsy (abst) 1406

Lymphocele, as transplantation complication (abst) 918Lymphocyte subsets

CAPD (abst) 1476TCRI (abst) 1482

Lymphocytic molecules, rosette phenomenon (abst) 465Lymphocytic response, post-rHuEPO therapy (abst) ... 1430Lymphokines, f32-m synthesis, amyloidosis, HD (abst).. 1409Lympholysis, cell-mediated, post-transplant (abst) 1427Lymphoma, non-Hodgkin allograft recipient (abst) 466LysoPAF metabolism in nephrotoxic nephritis 747

MMacrophages, peritoneal

function, different dialysate solutions (abst) 251function, low-calcium dialysate (abst) 251

Macrovascular disease, NIDDM, microalbuminuria(abst) 1397

Macula densa cells, Na/K cotransport, diuretics (abst)... 237MAG3 pharmacokinetics (abst) 1493Mg ions, arterial pressure changes (abst) 908Magnesium

dialysis concentration, erythrocytes, PTH (abst) 1404dietary, cyclosporine toxicity (abst) 254

Magnetoencephalography, CNS function analysis (abst).. 914Malarie Falciparum, acute renal failure (abst) 1455Malignant disease, allograft recipients (abst) 1191Malignant hypertension (abst) 1177, 1428Malignant pheochromocytoma (abst) 470Malnutrition, protein restriction, dialysis, 1139Manganese superoxide dismutase induction (abst) 242Mannitol, continuous intestinal dialysis (abst) 1188Mass transfer coefficient (abst) 1473Mastocites, pruritus treatment, ketotifeno (abst) 1415MDCK cells, transformed, K channel oscillations

(abst) 237Mean arterial pressure, CAPD (abst) 1394Medullary blood flow, humoral control (abst) 239Medullary thick ascending limb cells, inhibited by

cGMP 741

Membranes, hemodialysisAN69, anaphylactoid reactions (abst) 1481132-m synthesis, amyloidosis, lymphokines (abst) 1409biocompatibility, clinical implications 484biocompatibility, phagocytic action, HD (abst) 1466complement factor D adsorption (abst) 1187IL-i, TNF, IL-4, PBMC production (abst) 1187permeability, CAPD adequacy (abst) 1399platelet activation, fibrinolysis (abst) 1187PMMA, adhesion molecules, peripheral leukocytes

(abst) 1394polyacrylonitrile, complement factor D (abst) 260types, COPD ventilatory function (abst) 1462

Membranoproliferative glomerulonephritides (abst) 1185Membranous glomerulonephritis

anticoagulant factor protein S deficiency (abst) 1398idiopathic, non-treated (abst) 1438with nephrotic syndrome (abst) 249prednisone, clorambucil (abst) 1437

Membranous nephropathyaltered ECM synthesis (abst) 247children, post-transplant 43:S-91corticosteroids, Ponticelli's schedule (abst) 1462urinary C5b-9 excretion (abst) 250VLA (/3 integrin) distribution (abst) 1392

Membranous nephropathy, idiopathic (abst) 1424Menstrual function, post-transplant (abst) 913Mesangial cells

autocrine growth regulation, IL-6 (abst) 241AVP, Ang II, genetic expression (abst) 242CIQ complement, binding IgG, MC (abst) 1192cellular ATP mechanisms, Ca activity (abst) 241cytosolic free Ca, protein kinase C (abst) 1397gelatinase release, activation by plasmin (abst) 242glucose modulates ANP, Ang II actions 518HIV expression increased by TGF-f3 191LDL uptake, cholesterol metabolism (abst) 248mechanosensitive calcium channels (abst) 241PCR integrin, focal contact formation 997simvastatin, PDGF, DNA synthesis 503TGF-p increases HIV expression 1022TGF-f3l induces hypertrophy 948thromboxane receptors, protein kinase C 58TNF-a induces RANTES expression 795vascular permeability factor, PBMC 959

Mesangial matrix, metalloproteinase, GN (abst) 258Mesangial proliferative glomerulonephritis (abst) 1404Mesangial sclerosis, morphologic analysis (abst) 1406Metal ions and arterial pressure changes (abst) 908Metalloproteinases

inhibited by captopril 1266mesangial matrix, GN (abst) 258

Metals induce free oxygen radicals, HD (abst) 1437Metanephric development and IGF-IR 1242Methylprednisolone

ANCA-positive renal vasculitides 215inhibits OKT3 first-dose reaction (abst) 1485

Methylprednisone, OKT3, rejection, children (abst) .... 1454Microalbuminuria

essential hypertension, antihypertensives (abst) 246lisinopril, proteinuria, BP, glomerulopathy (abst) 1407macrovascular disease, diabetes (abst) 1397physical exercise (abst) 1446screening diabetics, proteinuria (abst) 1408

Microdialysis measures urea kinetics 622


Microscopic polyarteritis, renal involvement (abst) 906Mineral metabolism

children, CAPD (abst) 1465HD, calcium salts/dialysate (abst) 265

Mineralocorticoid deficiency, Addison's (abst) 1196Minimal change disease

children (abst) 1182FSGS, renal biopsy (abst) 905

Minocycline hydrochloride, renal cysts (abst) 1177Monoclonal antibody therapy, rejection (abst) 1416Monoclonal gammopathy, antilymphocytic globulins

(abst) 265Monocyte chemoattractant protein-I expression 1036Monocyte chemotactic peptide- 1, INF-y regulation 43Monocyte membrane antigen 48kDa excretion (abst) .... 249Monocytes, TNF-a, IL-6, rejection (abst) 256Muscarinic receptors, forearm vascular bed (abst) 1193Muscle glycogen content, CRF (abst) 1393Myocardial ischemia, hemodialysis (abst) 1411Myocardiopathy, uremic (abst) 1470Myopathy, liquorice abuse (abst) 1400

Nn-3 fatty acids, proteinuria, glomerular disease 843Na-2Cl-K cotransport, macula densa cells (abst) 237Na-a1anine cotransport, intracellular cations (abst) 238Na/H antiport

CsA activates, VSMC proliferation (abst) 254uremia, RBC 574

NafH exchange, l,25(OH)2D3, PTH (abst) 262Na ions, arterial pressure changes (abst) 908Na-K-ATPase

assay, cytosolic free sodium, RF (abst) 253ouabain sensitivity, rat nephron (abst) 262

Na/K cotransport, erythrocytes, liquorice abuse(abst) 1400

Na transport, clonidine, water transport, rat CCD 30Natriuresis

ANP, y-melanocyte stimulating hormone (abst) 472blunted volume expansion, Heymann nephritis (abst).. 472

Natriuretic hormone, non-peptidic, non-digitalis-like 937Neonatal

obstructive nephropathy 593sauna syndrome (abst) 1179

Nephntisacute hypersensitivity interstitial (abst) 1179autoreactive T cell clone regulation 692chronic tubulointerstitial 42:S-71karyomegalic interstitial, HLA-associated (abst) 259nephrotoxic, defective lysoPAF metabolism 747pathogenesis, complement deficiency 42:S-13radiation, renal protection (abst) 1421

Nephrolithiasismetabolic disorders (abst) 1461, 1494urinary sodium/creatinine, hypercalciuria (abst) 1445

Nephrologypediatric OPD clinic (abst) 1435program, Chile (abst) 1424

Nephropathyanalgesic 42:S-86lead, EDTA therapy (abst) 1487lead, experimental (abst) 1486, 1487obstructive, interstitial fibrosis 774puromycin aminonucleoside, rhGH 1281reflux, vesicoureteric reflux 42:S-80

Nephrosclerosispressure-dependent renin release (abst) 245therapy, nitrendipine with enlapanl (abst) 245

Nephrosis, post-transplant, CNF patients 867Nephrotic syndrome

adults, cyclosporine (abst) 1182amyloidosis 1183angiotensin inhibitors, protein diet (abst) 1415children, CsA toxicity (abst) 1182children, cyclosporin (abst) 906children, FSGS, follow-up (abst) 1182children, IL-2r, T-cell subsets (abst) 1182children, IL-4, mRNA expression (abst) 1182children, steroid resistant (abst) 256congenital, Finnish type 867coronary heart disease and 638diurnal rhythm, sodium excretion (abst) 11%hepatic cholesterol metabolism, rats 789idiopathic, use of sandimmune (abst) 265lipid metabolism, varied protein diet (abst) 1415lipoproteins 1116, 1182lipoproteins glomerular epithelial cells 1341with membranous glomerulonephritis (abst) 249prophylactic oral anticoagulants (abst) 265proteinuria, lovastatin, hyperlipidemia (abst) 1429refractory, CsA therapy (abst) 1434simvastatin, hypercholesterolemia, proteinuria 1124spondylo-epiphyseal dysplasia tarda (abst) 1395steroid resistant, CsA (abst) 905

Nephrotoxic nephritis, defective lysoPAF metabolism... 747Nephrotoxicity

cisplatin-induced, thyroxine effect (abst) 1178cisplatinum (abst) 251CsA, pediatric nephrotic syndrome (abst) 1182cyclosporine, dietary magnesium (abst) 254lithium 42:S-93ochratoxin A (abst) 251in vitro model 13

Neural control juxtamedullary arterioles 684Neuroleptic malignity syndrome and ARF (abst) 907Neutrophil chemotaxis, immunosuppression (abst) 1400Neutrophil elastase, CAPD peritonitis 87Neutrophils, Tamm Horsfall protein receptor 423Nifedipine

ankle edema, sodium retention (abst) 1194carbohydrate metabolism, CRF (abst) 1455

Nitrendipineessential hypertension (abst) 1469nephrosclerosis therapy (abst) 245

Nitric oxide (NO)glomerular hypersensitivity, dexamethasone (abst) .... 240

platelet dysfunction, dialysis hypotension 445renal blood flow, EPO-induced polycythemia 430synthase, distribution in kidney (abst) 240synthase expression, EC, MC (abst) 1489

Nodular glomerulosclerosis (abst) 471Non-Hodgkin lymphoma, donor related (abst) 466Non-insulin dependent diabetes (NIDDM)

hypertension, compared essential hypertension (abst). 1419insulin resistance, Na retention 139microalbuminuna, macrovascular disease (abst) 1397tubular enzymuria, cholinesterase activity (abst) 13%

Nonsteroidal anti-inflammatory drugs (NSAIDs)immunoallergic ARF, children (abst) 467renal complications, Nephrology Forum 643


North American Pediatric Renal TransplantCooperative Study 43 :S- 16, 43: S- 104

Nutritional statusCAPD, assessment (abst) 1412CAPD, peritoneal transport (abst) 1458CAPD (abst) 1458computer system assessment (abst) 1490diabetics, lipoproteins, HD (abst) 908maintenance HD (abst) 1459

01-a hydroxyvitamin D3, P1'H, HD (abst) 14111 ,25(OH)2D3

cellular immune response, CRF (abst) 1403intermittent/continuous exposure, chondrocytes 708NaIH-exchange, PTH inhibition (abst) 262parathyroid response 1259PTH, calcitriol pulse therapy, CAPD (abst) 1399PTH, T-cell expression, IL-2, HD (abst) 909PTH, T cell immunity, uremia (abst) 1391

Obesity, essential hypertension, CV risk (abst) 1419Obstructive nephropathy, interstitial fibrosis and 774Obstructive uropathy, post-transplant (abst) 1466Ochratoxin A, nephrotoxicity (abst) 251Oculo-renal syndrome without ANCA (abst) 1431OKT3 therapy

acute rejection steroid resistance (abst) 1479acute vascular rejection, plasma exchange (abst) 1416antibody formation (abst) 1482early rejection, HLA-identical recipients (abst) 468methylprednisolone (abst) 1485methyiprednisone resistance, children (abst) 1454prophylaxis with ATG-Fresenius (abst) 266T cell expression (abst) 1482

Oliguric ARF and furosemide (abst) 1451Ontogeny

CaBP-D28k mRNA in murine kidney 322cathechol-O-methyltransferase mRNA 726

Osmoregulation, collecting duct cells, hypertonicity 509Osteoarticular pain, epiphyseal impaction 98Osteoblast proliferation, desferoxamine (abst) 1497Osteocalcin levels, calcitriol, chronic HD (abst) 1408Osteodystrophy, renal

aplastic, without aluminum, "suppressed" PTH 860diabetic patients 159uremic diabetic patients (abst) 1435

Ouabain sensitivity, rat nephron, Na-K-ATPase (abst)... 262Ovariectomy, triglycerides, GS, analbuminemia (abst) .. 1193Oxidant-induced DNA damage to LLC-PKI cells 1228Ozone as contrast medium, renal angiography (abst).... 1449

PPAH-transporter, probenecid, cortisol release (abst) 238Paired filtration dialysis

kinetic modeling, sodium (abst) 1398plasma volume, isotonic/hypertonic solutions (abst) .. 1415

Pancreas transplantation, with renal transplant (abst).... 266Pancreatitis, post-transplant (abst) 1425Panel reactive antibodies, HD (abst) 913Panhypopituitarism

Addison's disease, glucocorticoids 1130Addison's disease, glucocorticoids (abst) 1196

Papillary interstitial cells, in culture (abst) 242Paraplegia, upper limb, metabolic study (abst) 1446

Parasites, stool (abst) 1471

Parathyroid glandsI ,25(OH)2D3 response 1259echographic study, HD (abst) 1438pre-operative localization (abst) 909

Parathyroid hormone (PTH)1,25(OH)2D3, calcitriol, CAPD (abst) 13991,25(OH)2D3, Na/H exchange (abst) 2621,25(OH)2D3, T-cell expression, IL-2, HD (abst) 909aplastic osteodystrophy, without aluminum 860bone histology, vitamin D3, radiology, ESRD 1071calcitonin, calcium stone formers (abst) 1397calcitriol, 22-OXA-I ,25D, Ca transport (abst) 467changes in ESRD, EPO therapy (abst) 1470dietary protein, CRF 173IGF-1, RF induced by protein diet (abst) 262optimal levels, uremia (abst) 1464platelet-activating factor, HD (abst) 916resistance to phosphaturic effect (abst) 238slowed secretion, urinary phosphate loss (abst) 465T cell proliferation, uremia 379

Parathyroid hormone-related peptide, renin secretion.... 764Parenchymal epithelial cells, antigen presentation 927Patlak graphical analysis, RBF quantification/imaging.... 985Peanut agglutinin, aldosterone, CD epithelium 537Percutaneous endoluminal angioplasty (abst) 470Percutaneous implantation, Tenckhoff catheter (abst).. . 1437Percutaneous transluminal angioplasty

hemodialysis fistula stenosis (abst) 1492renal artery, single functioning kidney (abst) 1426renovascular hypertension (abst) 911, 1426

Perforating dermatitis, HD (abst) 1443Perinatal asphyxia (abst) 1457Perinatal deaths, urinary tract anomalies (abst) 1176Peripheral blood mononuclear cells (PBMC)

cytokine networks, IgA nephropathy 1298IL-I, TNF, IL-6, dialysis membranes (abst) 1187vascular permeability factor, MC 959

Peripolar cell, glomerular 42:S-35Peritoneal catheter, Toronto Western Hospital (abst).... 919Pentoneal clearances, arterial pressure, CAPD (abst)... 1394Peritoneal dialysis

catheter migration (abst) 1477densitometry, histomorphometry (abst) 1449dialysate biocompatibility (abst) 1394gluconic acid as glucose substitute (abst) 1394intermittent versus HD, diabetes (abst) 1404

Peritoneal equilibration test (abst) 915Peritoneal kinetics, children, CAPD (abst) 1457Peritoneoscintigraphy multifocal accumulation (abst) ... 1189Peritonitis

CAPD, neutrophil elastase 87epidemiology, CAPD (abst) 914foreign body ileal perforation, CAPD (abst) 264fungal, Candida, PD (abst) 1452fungal, CAPD (abst) 1189fungal, chronic PD (abst) 468gram-negative, CAPD (abst) 1189incidence and !gG (abst) 1476peritoneal permeability (abst) 1197staphylococcus epidermidis, CAPD (abst) 915

pH balancecell volume, RAS oncogene expression (abst) 241changes in, Cl, AVP action, collecting tubules 1235hyperchloremic acidosis, transplantation (abst) 1397


Phagocytosisinhibition, HD 208membrane biocompatibility, HD (abst) 1466

Phenacemide, serum creatinine rise without RF (abst)... 464Pheochromocytoma, malignant (abst) 470Phosphatunc effect of PTH (abst) 238Phosphoglycolate phosphatase, diagnosis of ADPKD

(abst) 244Phospholipase A2

Ang-(l-7) action, tubular epithelium, Na transport 932glucocorticoids, protein/enzyme activity (abst) 263

Phosphorous, dietary, hyperparathyroidism (abst) 1428Picomole quantitation of sodium 875Piridoxine, carbohydrate metabolism, CRF (abst) 1456Plasma endothelin

concentration, hypertension (abst) 1178CRF (abst) 916

Plasma exchangeacute vascular rejection, OKT3 (abst) 1416Guillain-Barré syndrome 1443

Plasma membrane vesicles, renal ischemia (abst) 1178Plasma osmolarity, mannitol use (abst) 1422Plasma proteinase inhibitors, amyloid deposits (abst) .. . 1409Plasmapheresis, leptospirosis, CAPD (abst) 1452Plasminogen activator, LPS activation (abst) 258Platelet-activating factor, PTH influence, HD (abst) 916Platelet activation

13-glycosylated EPO, HD (abst) 912fibrinolysis, dialysis membrane effect (abst) 1187

Platelet clearance, immune complex-mediated ON 716Platelet-derived growth factor (PDGF)

glomerular expression, anti-GBM disease (abst) 905inhibition by simvastatin, MC 503

Platelet fatty acid cell membrane, RBC membrane(abst) 1391

Platelet fibrinogen receptor, impaired in ESRD (abst).... 252Platelet prostanoids, metabolic disturbances (abst) 914Platelets

cytosolic free sodium, essential hypertension (abst) ... 244dysfunction, NO, dialysis hypotension 445function, anemia (abst) 1484

Pneumocystis carini pneumonia, post-transplant (abst)... 264Pneumonia, respiratory syncytial virus (abst) 471Polyacrylonitnle membranes, complement factor D

(abst) 260Polyamide membrane, granulocyte activation (abst) 254Polyarteritis, microscopic

ANCA-positive, successful transplantation (abst) 469renal involvement, HLA antigens (abst) 906

Polycythemia, nitric oxide, renal blood flow, EPO 430Polydipsia, mechanisms in HD 107Polymerase chain reaction

detection of hepatitis C, HD (abst) 464indicates integrin expression, MC 997localizes renal ET-3 1273

Polymethylmethacrylate (PMMA) membrane (abst) 1394Polymorphonuclear cell decrease, CRF, HD (abst) 1450Polysulfone membrane, COPD ventilatory function

(abst) 1462Polyvinylpyrrilidone, dialyzer sterilization (abst) 1409Potassium

depletion, renal vascular induction 1006excretion, Addison's disease 1130excretion, Addison's disease (abst) 1196loading, adaptation, kallikrein-kinin system (abst).... 1454

Prednisolone/prednisone ratio in kidney 263Prednisone

clorambucil, membranous GN (abst) 1437cyclosporine triple therapy, graft function (abst) 1425hypertension therapy, Ca antagonists, ACEi (abst) ... 1439inhibits rhGH therapy, children, post-transplant ... 43:S-65withdrawal 43: S-30

Pregnancyacute renal failure (abst) 1431, 1441CRF, maternal/fetal complications (abst) 1469hypertension (abst) 1420, 1436, 1457outcome with CRF (abst) 466renal disease 42:S-64

Pressure-dependent renin release, nephrosclerosis(abst) 245

Primary glomerulopathy (abst) 1431Probenecid inhibits cortisol release (abst) 238Probucol, cyclosporine, pharmacokinetics (abst) 1403Procollagen- 1

bone metabolism, HD (abst) 909C-terminal extension peptide, HD (abst) 1396

Progressive glomerulosclerosis, TGF-/31, MC 948Proliferative autoimmune glomerulonephritis, rat model.. 294Prostacyclin analog, CsA glomerular vasoconstriction

(abst) 468Prostaglandin EP3 receptor, in situ hybridization 1372Prostaglandins, reverse renal vasoconstriction 1217Protein, acute oral load, albumin excretion (abst) 907Protein, dietary

angiotensin II, catecholamines 285angiotensin inhibitors, nephrotic syndrome (abst) .... 1415

CE!, antiproteinuric effect (abst) 1469CE!, diabetic nephropathy (abst) 1454children, CRF (abst) 1417intake equations, CAPD 1048muscle metabolism, amino acid supplementation

(abst) 465parathyroid hormone, CRF 173renal failure, IGF-I, PTH (abst) 262renal function, rats (abst) 1456renal vasodilation and 659restriction, malnutrition 1139uninephrectomy, renal injury (abst) 1454urinary excretion, lithogenic substances (abst) 1418urinary oxalate, glycolate excretion 366varied, lipid metabolism, nephrotic syndrome (abst) .. 1415

verapamil, nephrotic proteinuria (abst) 1469Protein catabolic rate (PCR)

adequacy tests on CAPD (abst) 464estimation by delta of volume (abst) 1417protein/caloric malnutrition, HD (abst) 1467

Protein content analysis renal stones (abst) 466Protein/creatinine index, assesses proteinuria (abst) .... 1434Protein kinase C

isoenzyme i mmunocharacterization (abst) 242MC culture, cytosolic free calcium (abst) 1397thromboxane receptors in glomeruli, MC 58

Proteinase 3, renal perfusion, ANCA (abst) 1194Proteinuria

abnormal lipoproteins, LCAT, CETP 91ACEi, renal hemodynamics 579ACEi, renal hemodynamics (abst) 1195assessment with protein/creatinine index (abst) 1434diabetic nephropathy, renal progression (abst) 1181Fabry's disease (abst) 1183


hemorrhagic fever with renal syndrome (abst) 1180heparan sulfate, renal hemodynamics (abst) 1192incidence/cause, post-transplant (abst) 1190lisinopril, microalbuminuria, glomerulopathy (abst)... 1407n-fatty acids, chronic glomerular disease 843nephrotic, hyperlipidemia, lovastatin (abst) 1429ovariectomy, GS, analbuminemia (abst) 1193prognostic meaning, post-transplant (abst) 1423screening diabetics, microalbuminuria (abst) 1408simvastatin, hypercholesterolemia, nephrosis 1124

Proteinuric factors in patient sera, detection (abst) 258Proximal tubular cells

non-selective cation channel properties (abst) 237renal ischemia, organic substance transport (abst). . .. 1178

Proximal tubular epithelial cellsbiosynthesis, complement C4, IFN-y 50inhibition of TNF-a production 352nephrotoxicity, in vitro model 13

Proximal tubulemetabolic alkalosis (abst) 1463protein with anion exchange properties identified 565

Pruritusin HD (abst) 1483membrane stabilizer of mastocites (abst) 1415uremic, serological markers, HD (abst) 1467

Psychogenic water intoxication, complications (abst) .. . . 471Pulmonary function, changes with EPO therapy (abst).. 1469Puromycin nephropathy

exacerbated by rhGH, rats 1281hepatic cholesterol metabolism, rats 789

QQuantitative electroencephalography (Q-EEG) 1109

RRadiation nephritis, renal protection (abst) 1421Radiologic studies, bone histology 1071RANTES and mesangial cells 795Rapamycin inhibits TNF-a production, PTEC 352Rapid, high-efficiency HD (abst) 917Reactive perforating collagenosis, ESRD (abst) 1405Recombinant growth hormone

children, post-transplant 43:S-62, 43:S-65, 43:S-71children, pre/post-transplant 43:S-76puromycin aminonucleoside nephropathy 1281renotropic effects with rhIGF-1 1251

Recombinant human erythropoietin (rHuEPO)administration, once-a-week (abst) 1485administration routes, HD (abst) 1430albumin-free, tolerance in CRF (abst) 1413anemia, post-transplant, chronic rejection (abst) 470anemia, pre-dialysis (abst) 1475children, anemia, CRF (abst) 1411children, pre-dialysis (abst) 1402endothelin, CRF 1478estimating Hb/Htc, anemia (abst) 1441functional capacity, CRF, HD (abst) 1416HBV vaccine, increased immunization (abst) 1430iron needs, dialysis (abst) 1476lymphocyte response (abst) 1430Q-EEG, event related potentials, CRF 1109

Recombinant insulin-like growth factor-I 1251Reconstitution of anion exchanger 565Red blood cells

antioxidant activity, blood glutathione, CRF (abst) .. . 1186

uremia, increased Na/H antiport activity 574Reflux nephropathy

vesicoureteric reflux 42:S-80vesicoureteric reflux, familial studies (abst) 1410

Rehabilitation, hemodialysis patients (abst) 1431Reinfection, urinary tract, prophylaxis (abst) 1434Renal acidification capacity, lithiasis (abst) 1418Renal angiography, ozone as contrast medium (abst) .. . 1449Renal arginine synthesis, CRF 676Renal artery

contrast media-induced constriction 1217embolism as cause of ARF (abst) 1462, 1480percutaneous angioplasty (abst) 1426pressure, EDRF, renin release (abst) 240stenosis, captopril scintigraphy (abst) 1495stenosis, diagnosis, echo-doppler (abst) 1393

Renal biopsyacute hypersensitivity interstitial nephritis (abst) 1179findings with systemic vasculitis (abst) 1429follow-up, 1000 cases (abst) 1181FSGS, minimal change disease (abst) 905percutaneous, complications (abst) 1470percutaneous, new technique (abst) 1416percutaneous, post-transplant (abst) 1420percutaneous, ultrasound (abst) 1458

Renal blood flow, humoral control (abst) 239Renal calculi, hypocitraturia (abst) 1442Renal cell carcinoma

cytokine expression 585hereditary, Von Hippel-Lindau syndrome (abst) 250

Renal cell nuclei, ET-1 receptors (abst) 239Renal clearance, inulin 1058Renal cortex, proteolytic enzymes, CsA (abst) 254Renal cysts, aspiration-scierotherapy (abst) 1177Renal disease

48kDa monocyte membrane antigen excretion (abst)... 249cadmium exposure (abst) 250cholera and (abst) 1410familial Mediterranean fever 834HIV infection and (abst) 466inherited, molecular approach 1205microscopic polyarteritis, HLA antigens (abst) 906NSAIDs as cause of, Nephrology Forum 643pregnancy 42:S-64progressive, endothelin subtype antagonism 440scrub typus, uremia (abst) 1179

Renal erythropoietin-producing cells, mice 1149Renal failure

citrate, aluminum absorption (abst) 253contrast media-induced, theophylline (abst) 251erythropoiesis, aluminum accumulation (abst) 1463induced by triamterene-thiazide (abst) 464intrarenal pressure, post-transplant (abst) 1421neonatal heat stress (abst) 1179pretranscriptionally IL-6 production (abst) 254progression, additional renin gent, rat (abst) 244tetanus, rhabdomyolysis (abst) 1426treatment, socio-ethical aspects, Latin America 1450

Renal functionantihypertensive agents, systolic hypertension (abst)... 911atenolol, captopril, DM nephropathy (abst) 1197dialysis-free interval (abst) 1196endothelin, rabbits (abst) 263hyperproteic diet, rats (abst) 1456hypertension and 42:S-52


intrarenal renin-angiotensin system 42:S-59long-term, post-nephrectomy (abst) 249Na-lithium countertransport, IgA nephropathy (abst) .. 906PTH-induced decline, protein diet, IGF-I (abst) 262quantification (abst) 1493thyroxin administration, hypothyroidism (abst) 1195

Renal functional reserverenin-angiotensin system, transplantation 165renin-angiotensin system (abst) 239

Renal gene expression 42:S-47Renal gene therapy, mammalian kidney (abst) 1419Renal growth regulating factors, PTC cultures (abst)... . 1443Renal hemodynamics

altered, heparan sulfate, proteinuria (abst) 1192antiproteinuric effect, ACEi (abst) 1195arterial blood pressure, isradipine (abst) 1429ibopamine, congestive heart failure (abst) 1196proteinuria, ACE inhibition 579quantification/parametic imaging 985vasodilation and protein feeding 659

Renal hypertrophydiabetes, intralysosomal proteinases (abst) 248intracellular proteinases (abst) 247

Renal injurychronic interstitial, grey level granulometry (abst). . . . 1450leukocyte-endothelial cell adhesion molecules 42:S-27remnant kidney, dietary protein (abst) 1454scarring, vesicoureteric reflux (abst) 1409

Renal ischemiaorganic substance transport, rabbit PTC (abst) 1178warm, superoxide dismutase liposomed (abst) 1428

Renal mass reduced, ACEi, brain ANF 24Renal microcirculation, endothelin, EDRF (abst) 1393Renal net acid excretion, urinary stone risk factors 120Renal osteodystrophy

calcitriol, CRF (abst) 909calcium kinetic studies (abst) 909compared, HD and CAPD (abst) 910hydroxyvitamin D3, HD (abst) 910post-peritoneal dialysis (abst) 1449

Renal protection, radiation nephritis (abst) 1421Renal stones

2,8-dihydroxyadenine, post-transplant (abst) 1198hypercalciuria, PTH, calcitonin (abst) 1397idiopathic calcium, low bone mass (abst) 264protein content analysis (abst) 466recurrence (abst) 1442risk factors, calculation titratable acidity 120

Renal surgery, laparoscopic 273Renal vascular

induction, TGF-f32 and renin 1006tone, ET-l receptor, EDRF (abst) 239

Renal vasculitides, ANCA-positive, steroids 215Renal vasoconstriction

contrast media induced, ET, prostaglandins 1217EDRF synthesis, endotoxemia (abst) 1194

Renal vasodilation, protein feeding and 659Renin

additional gene, RF progression, rat (abst) 244adrenal microadenomas, aldosterone (abst) 916determination, renovascular hypertension (abst) 1448hypertension, diagnosis/treatment, Nephrology

Forum 1163immunohistochemical detection, ADPKD (abst) 243secretion, PTH-related peptide induced 764

secretion, vascular endothelial role (abst) 240TGF-/32, renal vascular induction 1006

Renin-angiotensin systemdetection, mRNA and protein level (abst) 240intrarenal, physiology/pathophysiology 42:S-59oncogene expressing cells, Ca1, pH regulation (abst)... 241regulation, with ureteral obstruction 390renal functional reserve, transplantation 165renal functional reserve (abst) 239

Renotropic activity, post-uninephrectomy (abst) 1177Renotropic effects, rhGH and rhIGF-1 1251Renovascular hypertension

ACE, Ang II receptors (abst) 245ACE modulation (abst) 245ACEi for diagnosis, Nephrology Forum 1379captopril test, renin determination (abst) 1448control, post-PTA (abst) 911incidence, treatment (abst) 1416percutaneous transluminal angioplasty (abst) 1426urinary ACE, diuretics (abst) 1420

Respiratory function, COPD, HD (abst) 1462Respiratory infection

syncytial virus pneumonia, post-transplant (abst) 471transplantation (abst) 1422

Retransplantation risk factors (abst) 918, 1473, 1479Rhabdomyolysis, tetanus, renal failure (abst) 1426RNA synthesis in uremia 385Rosette phenomenon, antilymphocyte globulins (abst) ... 465

SSalbutamol, controls acute hyperkalemia (abst) 1412Salt

high intake, BP response (abst) 246sensitivity, insulin resistance (abst) 246

Sandimmune, idiopathic nephrotic syndrome (abst) 265Schistosomal glomerulopathy 1

Schistosomal glomerulopathy (abst) 1426Sclerosing peritonitis, CAPD (abst) 919Self-induced water intoxication (abst) 471Sepsis, acute renal failure and (abst) 1430Septic abortion, acute renal failure (abst) 1424Simvastatin

hypercholesterolemia, CsA therapy (abst) 1438hypercholesterolemia, nephrosis, proteinuria 1124hypercholesterolemia, rejection (abst) 1497inhibits PDGF-induced DNA synthesis, MC 503

Skeletal muscle metabolism, protein/amino acid intake(abst) 465

Sodiumdietary, hypercalciuria, nephrolithiasis (abst) 1445excretion, diurnal rhythm, NS (abst) 1196extracellular, AVP-induced [Ca2] increase 755kinetics modeling, paired filtration dialysis (abst) 1398millimolar concentrations, nanoliter samples 875overload, hypertension, DM nephropathy (abst) 1428

Sodium-lithium countertransportrenal function, IgA nephropathy (abst) 906triglycerides, DM nephropathy 127

Sodium retentionankle edema, nifedipine (abst) 1194insulin resistance, NIDD 139

Sodium transport, Ang-(1-7) action, phospholipase 932Spondylo-epiphyseal dysplasia tarda, NS (abst) 1395Staphylococcus epidermidis, peritonitis, CAPD (abst) ... 915Stents, intravascular, post-insertion infection (abst) 470


Steroid resistant nephrotic syndromechildren, transplantation (abst) 256cyclosporin A therapy (abst) 905

Steroid withdrawalHLA matching, LRD/cadaver donors 43:S-30metabolic effects, adults 43:S-26protocol, children 43:S-36

Steroidsacute rejection resistance, OKT3 therapy (abst) 1479ANCA-positive renal vasculitides 215azathioprine, CsA double therapy (abst) 1443azathioprine, hepatitis B reactivation (abst) 1427

Streptozotocin-induced diabetesangiotensin hR-gene expression, rats (abst) 1392decreased ANP receptors (abst) 471lovastatin prevents OS (abst) 1181

Subcutaneous tunnel infection, CAPD (abst) 915Sulfamethoxazole-trimethoprim, GN (abst) 1183Superoxide dismutase, renal warm ischemia (abst) 1428Survival probability, non-parametric estimation (abst) .. 1490Swan neck peritoneal catheters (abst) 1403, 1472Syncytial virus, respiratory pneumonia (abst) 471Syndrome of inappropriate secretion of antidiuretic

hormone (SIADH) 19Synergistic immunosuppression, children 43:S-12Synovial fluid, IL-2R levels, arnyloidosis (abst) 1395Systemic lupus erythematosus (SLE)

glomerulonephritis, compared HBV GN (abst) 1185renal function post-pulse cyclophosphamide (abst) .... 906T cell clones from lupus nephritis (abst) 1441

T99mTc..DTpA GFR assessment (abst) 119099mTc..HSA cardiac gated blood pool scan (abst) 1186T cells

activation defect, B7/CD28 pathway, hemodialysis .... 359antigen presentation, parenchymal cells 927clones, self-regulation autoreactive 692clones isolated, lupus nephritis, SLE (abst) 1441expression, OKT3 therapy (abst) 1482expression, PTH, 1 ,25(OH)2D3, IL-2, HD (abst) 909graft infiltration, antigen recognition (abst) 1193hemorrhagic fever with renal syndrome (abst) 1180immunity variations, 1 ,25(OH)2D3, uremia, PTH

(abst) 1391proliferation, PTH-dependent, uremia 379proliferation, TEC, superantigens (abst) 243signaling, anti-allograft response, children 43:S-3TEC induce anergy 1030

Tamm-Horsfall proteinbinds IgG with high affinity 1014citrate, calcium, COM crystal aggregation (abst) 263receptor on neutrophils 423synthesis, hyperprostaglandin E-syndrome 401

Tenckhoff cathetersCAPD (abst) 919percutaneous implantation (abst) 1437

Tetanus, renal failure, rhabdomyolysis (abst) 1426TGF-f3-l mRNA, obstructed kidney 313Theophylline

erythrocytosis, post-transplant (abst) 918prevents contrast media-induced RF (abst) 251

Thick ascending limb (TAL) cellsadaptation to metabolic alkalosis (abst) 1463depolarized by ammonium, inhibited K-channel

(abst) 237

medullary, inhibited by luminal cGMP 741as source of adenosine (abst) 239

Thrombosis risk, EPO therapy, HD 182Thromboxane receptors, protein kinase C, glomeruli 58Thyroid hormones

stimulate EPO production (abst) 238therapy, hypothyroidism, renal function (abst) 1195

Titratable acidity calculation 120Toronto Western Hospital pentoneal catheter (abst) 919Transcranial Doppler diagnosis, brain death (abst) 1459Transforming growth factor-a

glomerular expression, PDGF, anti-GBM disease(abst) 905

HIV expression, mesangial cells 1022Transforming growth factor-fM, MC hypertrophy 948Transforming growth factor-f32, renin, K depletion 1006Transplantation

2,8-dihydroxyadenine stone formation (abst) 1198"Tc-DTPA, GFR assessment (abst) 1190acquired cystic kidney disease, CsA 613acute pancreatitis (abst) 1425ANCA-positive, microscopic polyarteritis (abst) 469anemia after (abst) 1423antilymphocyte globulin, graft function (abst) 913azathioprine-induced leukopenia, GM-CSF (abst) .... 1191

Banff classification, allograft rejection 411Bolivia (abst) 1435bone disease (abst) 267bone marrow, ARF (abst) 1477bone mineral density, HD (abst) 1457cadaver graft survival, Hispanoamerica (abst) 1405cadaver grafts (abst) 1473cardiovascular/cerebrovascular complications (abst) .. 1464Chagas disease (abst) 1461, 1462children, ages one to five years 43:S-40children, cadaver grafts 43 :S-99children, cyclosponne dosing 43:S-SOchildren, five-year survival 43:S-16, 43:S-22children, growth, long-term follow-up 43:S-56children, growth hormone therapy 43:S-62, 43:S-65,

43:S-71, 43:S-76children, growth suppression, steroids 43:S-59children, hospitalization after 43:S-83children, immunizations 43:S-87children, recurrent disease 43:S-91children, steroid resistant NS (abst) 256children (abst) 1435Chile (abst) 1444clinical course, HBV and HCV (abst) 1189CMV detection in urine (abst) 1402CMV diagnosis methods 256CMV markers (abst) 1403CMV prophylaxis (abst) 1425color Doppler sonography evaluation (abst) 466complications, surgical (abst) 918, 1468computer systems (abst) 1490, 1491corynebacterium urealyticum (abst) 1496creatinine clearance, GFR marker (abst) 1434DM, impaired glucose tolerance (abst) 1443DM nephropathy, outcome (abst) 267epiphyseal impaction after 98evolution EPO serum levels (abst) 1433flow cytometnc cross match 1393follow-up in 505 cases (abst) 912future directions, xenotransplantation 42:S-1 12


glomerulopathy, incidence/evolution (abst) 1439glomerulopathy, morphologic analysis (abst) 1406graft function, calcium antagonists (abst) 913haploidentical patients (abst) 1435HBV reactivation, immunosuppression (abst) 1427HCV and CMV antibodies, HD (abst) 1430HCV prevalence (abst) 914HLA-identical recipients, OKT3 (abst) 468hypertension management 43:S-45hyperuricemia, benziodarone (abst) 1480hypophosphatemia (abst) 1483IgA, IgG2a anti-CD3 isotype switch variants (abst)... 1198IL-6 determinations, diagnostic value (abst) 256immunosuppression, lipid levels (abst) 1198immunosuppression, prophylactic, OKT3, ATG-F

(abst) 266infections with triple immunotherapy (abst) 914infectious disease complications, Nephrology Forum . . 221influenza vaccination (abst) 918intrarenal pressure determination (abst) 1421Kaposi's sarcoma (abst) 918Latin American program (abst) 1450leukopenia, treatment (abst) 1479lipid abnormalities, uremia, HD (abst) 1441lipid metabolism (abst) 1474lipoprotein(a) concentration, CRF (abst) 1190living donors, outcome (abst) 1468living unrelated donors (abst) 1398long-term renal function, cadaver donors (abst) 1439lower gastrointestinal perforations (abst) 913lymphocele as complication (abst) 918menstrual function (abst) 913obstructive uropathy (abst) 1466organ exchange, HLA matching (abst) 1480pancreas/kidney, lipid levels (abst) 266pneumocystis carini pneumonia (abst) 264Priscilla Kincaid-Smith, contributions of 42:S-99proteinuria, incidence/cause (abst) 1190proteinuria, prognostic meaning of (abst) 1423PTH secretion, urinary phosphate loss (abst) 465recurrent ON, prognosis (abst) 257renal functional reserve, RAS 165respiratory infection (abst) 1422rHuEPO therapy for chronic rejection (abst) 470risk factors, retransplantation (abst) 918screening diabetics for CAD 617selection criteria (abst) 1432before starting dialysis (abst) 1440steroid withdrawal 43:S-30steroid withdrawal, children 43:S-36steroid withdrawal, metabolic effects, adults 43:S-26survival rates, Argentina (abst) 1414survival rates, non-parametric estimation (abst) 1490survival rates, Spain (abst) 1480survival rates, Uruguay (abst) 1422theophylline, erythrocytosis (abst) 918tuberculosis, distribution (abst) 1458urinary fistula after 1463urinary fistula after (abst) 1494urinary obstruction after (abst) 1463, 1493viral pneumonia (abst) 471

Triamterene-thiazide association, renal effects (abst) .... 464Triglycerides

ovariectomy, GS, analbuminemia (abst) 1193sodium-lithium countertransport, DM nephropathy.... 127

Tryptophan, free/protein-bound, CRF 1366Tuberculosis (abst) 1458Tubular acidosis, induced by cadmium (abst) 1176Tubular epithelial cells

Ang-(l-7) action, phospholipase A2, Na transport 932IFN-y-activation, lupus nephritis (abst) 1441induce CD4 T cell anergy 1030superantigens, stimulate T cell proliferation (abst) 243

Tubule interstitial disease (abst) 1451Tubulointerstitial nephritis, chronic 42:S-71Tumor markers, long-term changes, HD (abst) 917Tumor necrosis factor-a

expression, renal cell carcinoma 585HLA-antigens (abst) 1486IL-6, HD (abst) 1495IL-6, monocyte production, rejection (abst) 256IL-6, monocyte release, uremia (abst) 1392induces RANTES, mouse mesangial cells 795mRNA expression, rejecting allograft biopsy (abst).... 255production by proximal tubule EC 352transplant rejection, in situ hybridization (abst) 468

Tumor necrosis factor (TNF)induction, dialysis membrane effect (abst) 1187PBMC production, dialysis membrane effect (abst)... 1187

Typhus, renal dysfunction, uremia (abst) 1179

UUltrafiltration

CAPD, peritoneal membrane changes (abst) 914HD, L-carnitine, vascular refilling (abst) 260

Ultrasonic percutaneous renal biopsy (abst) 1458Unilateral kidney, hypertension (abst) 1449Uninephrectomy

acute oral protein load, albumin excretion (abst) 907remnant kidney injury, dietary protein (abst) 1454renotropic activity, renal/hepatic roles (abst) 1177

Ureabounce, dialysis parameters and (abst) 1417estimation by delta of volume (abst) 1417percentage reduction, adequacy HD (abst) 1436

Urea clearanceHD, stable/variable sodium dialysate (abst) 264overestimation in dialysis prescription (abst) 1427

Urea kinetic modelingadequacy of dialysis (abst) 260, 916clinical application (abst) 1186dialysis parameters adjustment (abst) 1417dialysis time, females/males (abst) 1484KT/V index (abst) 1188, 1436

Urea kineticsdouble lumen catheter, HD (abst) 1443measured by microdialysis 622

Uremiacontinuous intestinal dialysis, mannitol (abst) 1188diabetes, renal osteodystrophy (abst) 1435DNA repair 385EPO therapy, anemia, not on dialysis (abst) 1434erythrocytic dysmorphism, aluminemia, HD (abst) ... 1400extrarenal calcitriol synthesis 134hyperlipidemia, gemfibrozil treatment, HD (abst) 1419increased Na/H antiport activity, RBC 574lipid abnormalities transplantation, HD (abst) 1441

LVH, antihypertensive therapy 881NO, platelet dysfunction, dialysis hypotension 445non-diabetic, aluminum, adynamic IDDM (abst) 1445


optimal iPTH levels (abst) 1464scrub typhus, renal dysfunction (abst) 1179T cell immunity, l,25(OH)2D3, PTH (abst) 1391I cell proliferation, PTH-dependent 379

Ureteral obstructionneonatal, collagen studies 593regulation of RAS 390serum hippuric acid, allograft rejection (abst) 261TGF-f3-l mRNA 313

Urinalysismicroscopic, GN 42:S-9specimen storage for enzymatic assay (abst) 1396

Urinary C5b-9 excretion, membranous nephropathy(abst) 250

Urinary concentration, perinatal asphyxia (abst) 1457Urinary enzymes, specimen storage for assay (abst).... 1396Urinary fistula

post-transplant (abst) 1463, 1494Urinary obstruction

post-transplant (abst) 1463, 1493Urinary oxalate, protein intake, glycolate excretion 366Urinary phosphate loss, PTH, transplantation (abst) 465Urinary sodiumlcreatinine, nephrolithiasis (abst) 1445Urinary tract anomalies, perinatal deaths (abst) 1176Urinary tract infection (UT!)

index of reinfection, prophylaxis and (abst) 1434prevalence, HD (abst) 1488prophylaxis, ceftriaxone/aztreonam-cloxacillin (abst). 1440

Urolithiasischildren, metabolic study (abst) 1414children (abst) 1455

UTP, ATP analogues, phospholipase C (abst) 258

VVascular access

AV fistula, femoral (abst) 470AV fistula, recurrent clotting (abst) 469double-lumen catheter, permanent, percutaneous

(abst) 259double-lumen catheter, urea kinetics (abst) 1443double-lumen catheter (abst) 1414fistula survival factors, HD (abst) 1187infection post-stent insertion (abst) 470prostheses (abst) 1491stenosis, PTA (abst) 1492twin femoral catheters (abst) 470two-year experience (abst) 1452

Vascular cell adhesion molecule- 1 expression 805Vascular endothelial growth factor, mesangial, PBMC... 959Vascular smooth muscle cells

calcium channel/intracellular activity, rats (abst) 1393glucose elevation, calcium ion uptake 344intracellular calcium pools, hypertension (abst) 244proliferation, CsA, Na/H-antiport (abst) 254

VasculitisANCA-positive, prevalence, dialysis (abst) 252pathogenesis, complement deficiency 42:S-13systemic, renal biopsy findings (abst) 1429

Vasoactive hormones in protein deprivation 285Ventricular arrhythmias, double-lumen catheter

insertion (abst) 1481

VerapamilACEi, hypertension (abst) 1439nephrotic proteinuria, protein intake (abst) 1469

Vesicoureteric refiuxreflux nephropathy 42:S-80refiux nephropathy, familial studies (abst) 1410renal scarring (abst) 1409

Vessel wall properties, non-invasive measurement(abst) 252

Vitamin B6, carbohydrate metabolism, CRF (abst) 1456Vitamin D3

bone histology, radiology, PTH, ESRD 1071long-term therapy (abst) 1452

VLA-3 distribution, membranous nephropathy (abst) ... 1392

Von Hippel-Lindau syndrome (abst) 250Von Willebrand factor (abst) 1195

wWater intoxication, complications (abst) 471Water transport

CAPD 700Na, clonidine, rat CCD 30

Wegener's granulomatosisANCA, microscopic polyarteritis (abst) 469ANCA, renal perfusion, proteinase 3 (abst) 1194GN, sulfamethoxazole-trimethoprim (abst) 1183

xXenobiotics, nephrotoxicity 13

Xenotransplantation 42:S-1 12

zZinc levels, anemia, CRF, HD (abst) 1484

subject index for volume 44 - core.ac.uk · anemia arf, endogenous epo deficit (abst) 1411 ... (...

Documents